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Abstract 
Background: Pain is a major clinical problem, the true prevalence of which is difficult 
to estimate as it encompasses a variety of disorders. Sciatica is considered a type of 
neuropathic pain (NP) characterised by severe low back pain radiating down the leg 
to below the knee. Chronic sciatica (CS) is sciatica lasting longer than three months. 
There are few clinical guidelines for treating of CS, reflecting a gap in quality evidence 
for effective therapies. Recently, two medications gabapentin (GBP) and pregabalin 
(PGB) have been used in the management of CS. Evidence for their usage is limited 
with no direct, high quality research to determine if one is superior to the other. This 
research answers that question and helps guide clinicians as to the best treatment 
option for CS. 
Methods: The thesis includes a literature review to gauge current management of CS 
with PGB and GBP. The work uses a mixed-methods approach to gain evidence on 
efficacy, disability and personality traits which will guide clinician’s choice of either 
GBP or PGB. A mix of methods was chosen, to capture patient’s treatment 
experiences more broadly and not simply being restricted to symptom relief. Anecdotal 
evidence suggests a variable response to either drug, both in terms of efficacy and 
adverse events (AEs). However, we are unsure at what point the balance of benefits 
against AEs tips and patients make the decision to abandon treatment. To gather this 
information and draw conclusions regarding the optimal treatment for patients with CS, 
this project collects background information on patient’s perceptions related to 
treatment, and conducts a novel randomised controlled trial to determine head to head 
which treatment is more efficacious. We set out to establish whether one drug has a 
superior profile to the other and if there are any other differences in treatment 
outcomes. 
Hypothesis: We hypothesise that there are differences between the drugs, where (1) 
one drug (PGB) has a superior profile in pain and disability reduction, as well as (2) 
frequency and severity of adverse events.  
Results: Retrospective data showed AEs to be a limiting factor for treatment outcomes 
and compliance when GBP was added to a first line agent. The clinical trial reported 
here showed that, while PGB and GBP were both significantly efficacious in reducing 
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pain intensity in patients with CS, GBP was superior when compared ‘head-to-head’. 
Moreover, GBP was associated with fewer and less severe AEs. Neither drug was 
superior when compared ‘head-to-head’ for reducing disability in our study group. Our 
exploratory study on personality traits showed that patients with a predominantly 
external self-control had worse outcomes. Specifically, an external self-control 
resulted in lower pain severity reductions especially with PGB. Moreover, PGB alone 
demonstrated a high, and statistically significant, positive correlation with external self-
control resulting in higher pain values for patients displaying this personality trait. 
There were no notable differences between drugs when personality and disability 
severity were compared.  
Conclusion: This research makes a significant original contribution to the literature by 
addressing a key gap regarding the utilisation of pain medication for CS, namely with 
PGB and GBP. We found that GBP was superior to PGB for reducing pain severity 
and for being associated with fewer and less severe AEs. Moreover, our results show 
having a personality trait of external locus of self-control, negatively effects treatment 
outcomes with PGB. Our findings provide a body of evidence which can formally guide 
treatment decisions for patients with CS considering pain severity, disability severity, 
AEs and personality. 
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Chapter 1 Introduction 
‘The aim of the wise is not to secure pleasure, but to avoid pain.’ 
Aristotle 
1.1 Context of this Research 
Neuropathic pain (NP) is a major clinical and epidemiological problem, the prevalence 
of which is difficult to estimate as it encompasses a variety of disorders. Sciatica is 
considered a type of NP characterised by severe low back pain with radiating leg pain 
below the knee and considered a major clinical problem (3, 15). Chronic sciatica (CS) is 
sciatica lasting longer than 3 months (14).  There are few clinical guidelines on the 
treatment of CS, reflecting the lack of quality evidence of effective therapies. Recently, 
two medications gabapentin (GBP) and pregabalin (PGB) have been used in the 
management of NP but there is limited, direct, high quality research to inform clinicians 
as to which of these to choose for the treatment of people with CS.  
GBP and PGB both belong to the anti-convulsant class of medications. The exact 
mechanism of action is unknown; however, they are believed to bind to alpha-2 delta 
protein subunit of high threshold voltage-dependant calcium channels, reducing 
calcium influx and neurotransmitter release (5). Consequently, a decrease in pain is 
observed in neuropathic aetiologies. Both GBP and PGB are titrated up to the 
maximum tolerated dose with GBP administered three times per day (tds) and PGB 
twice per day (bd) (5). For NP, PGB is capped at 300mg bd while GBP is 1.2g tds (5). 
Common adverse effects are similar between the medications and feature fatigue, 
sedation, dizziness, ataxia, tremor, diplopia, weight gain, dry mouth, hypertension and 
rash (5).  
This thesis entails a mixed-methods approach to gain evidence on efficacy, disability 
and personality traits which will guide clinician’s choice of either GBP or PGB. We have 
chosen a combined approach, designed to capture patient’s treatment experience 
more broadly, not simply focussing on symptom relief. Anecdotal evidence suggests 
a variable response to either drug, both in terms of efficacy and adverse events (AE). 
However, we are unsure at what point the balance of benefits against AE tips and 
patients make the decision to abandon treatment. To gather this information and draw 
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conclusions regarding the optimal treatment for patients with CS, this project (1) will 
collect background information on patient’s perceptions related to treatment, and (2) 
conduct a novel randomised controlled trial to determine head to head which treatment 
is more efficacious.  
In terms of efficacy and AEs, we set out to establish whether one drug has a superior 
profile compared to the other. Conversely, we expect to encounter patients who 
abandon treatment after a short period with minor adverse events (AEs).  
 At the completion of this research, the aim is for a gap in the literature to be filled 
regarding the efficacy of PGB compared to GBP, and evidence made available to help 
guide treatment decisions based on disability severity and personality types for each 
patient. 
1.2 Justification for the Research 
Sciatic neuralgia (also known as sciatica), is a common form of lumbosacral 
radiculopathy. This condition is characterised by low back pain that radiates to the leg 
below the knee and can be accompanied by sensory loss, motor weakness and reflex 
abnormalities. Sciatica is a form of 'neuropathic' pain (NP) caused by compression or 
irritation of the roots of nerves that together comprise the sciatic nerve. CS is NP that 
has been present for more than three months. CS often complicates previous chronic 
low back pain (CLBP): however, it may present as an isolated phenomenon (4, 10).   
CS is considered to be a prognostic indicator of poor outcome among patients with 
low back pain with a substantial proportion continuing to have persistent pain for two 
years or more. The annual prevalence of CS is estimated to be between 1.6% and 
43% (4, 14). While guidelines provide clear and generally consistent recommendations 
for the prescription of drugs for non-specific low back pain, this is not the case for CS. 
CLBP can often be managed with simple analgesic regime that includes paracetamol, 
non-steroidal anti-inflammatory agents (NSAIDs) (e.g. ibuprofen), or opioid analgesics 
(e.g. codeine or tramadol). CS, however, like most NP states, is often resistant to such 
conventional analgesics (4, 10). NP is typically managed by add-on therapy of anti-
convulsant drugs onto simple drug regimens: the drugs most commonly used are GBP 
or PGB.  CS, an example of a NP state, is therefore increasingly being treated with 
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super-added GBP or PGB (4, 10). Both are analogues of Gamma-Aminobutyric Acid 
(GABA) that modulate calcium-channel subunits, possibly decreasing 
neurotransmitter release associated with the central sensitisation that occurs in CS. 
Background evidence suggests GBP is superior to placebo for patients experiencing 
pain from the NP state of radiculopathy. In a phase 2 trial, GBP (900-3600mg) showed 
significant overall pain relief in the short term (mean diff -26.6, -38.3 to -14.9; P<0.001)  
(10). In a recent systematic review for the prevention of chronic postsurgical pain, of the 
8 included trials, 4 reported GBP resulted in lower incidence of pain and/ or lower 
analgesic requirements. It was also found by extrapolation that GBP use would 
improve long-term functional status in the population studied (2). A study of neuropathic 
cancer pain, showed a significant decrease in the pain visual analogue score (VAS) in 
the group administering GBP (7.5 to 3.0)(7). The National Institute of Clinical 
Excellence (NICE) Neuropathic Pain Guidelines reports that GBP, when used as 
monotherapy in placebo-controlled trials, results in patients experiencing a 50% 
reduction in pain (9). 
In previous clinical trials PGB provided significant pain relief and improved quality of 
life in both post herpetic neuralgia and painful diabetic neuropathy. Eight studies 
examined varying doses of PGB on post herpetic neuropathic pain which 
demonstrated an average relative benefit to placebo of 2.5 (1.9 to 3.4) and at least 
50% pain relief number needed to treat (NNT) of 5.3 (3.9 to 8.5) (13). For diabetic 
neuropathic pain, PGB has a dose-dependent clinical efficacy and appears not to be 
effective at 105mg per day dose and only slightly effective at higher doses (1.6 ( 1.4 
to 1.9) and a NNT of 6.3 (4.6 to 10.3)) (13). A meta-analysis of randomised placebo-
controlled trials confirms PGB’s efficacy to significantly reduce subjective pain for 
neuropathic conditions (8). 
The precise role of PGB or GBP in CS has been surprisingly under-explored (1). Most 
patients with chronic pain and neuropathic component, however, typically also take an 
antidepressant (such as Amitriptyline) in their drug regime (10). Super-adding either 
GBP or PGB could produce or exacerbate AEs in such cases (10). Nevertheless, 
despite some AEs, most patients typically continue to tolerate GBP or PGB because 
of the pain relief (12). While ceasing concurrent medication would undoubtedly 
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ameliorate AEs with either PGB or GBP, most patients are understandably reluctant 
to stop drugs that reduce pain (12). 
It is important to note that in current clinical practice, either PGB or GBP would be the 
next treatment offered after conventional analgesics: either as an alternative to surgery 
(with its greater risks), or as a penultimate step before committing to surgery. It is 
important to note that a position of equipoise exists in clinical practice regarding which 
drug (i.e. PGB or GBP) to prescribe in this situation.  We believe that it is important 
and timely to establish the best choice in a scientific manner for the benefit of all CS 
patients.  
1.3 Aim 
The aim of this thesis is to investigate the pharmacological management of CS, 
including the utilisation, adverse events and efficacy of two key pain medications, PGB 
and GBP.  
1.4 Hypotheses 
H1- There is a difference between PGB and GBP, in terms of reducing pain and 
disability severity when used for the treatment of CS. 
H2-  There is a difference between PGB and GBP in terms of frequency and 
severity of adverse events when used for the treatment of CS. 
H3-  Personality traits influence treatment outcomes with PGB and GBP when used 
for the treatment of CS. 
H0-   There is no difference between PGB and GBP when used for the treatment of 
CS. 
1.5 Objectives 
• To confirm that PGB and GBP are efficacious in treating CS. 
• To determine whether one medication (i.e. PGB or GBP) is superior over the 
other in terms of treatment efficacy for CS. 
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• To determine whether one medication is superior over the other (PGB or 
GBP) in terms of frequency and severity of AEs. 
• To determine whether personality traits influence treatment outcomes with 
PGB and GBP. 
1.6 Methodology 
The study consists of three parts: 
Part one  
A review of the literature to compile up-to-date evidence concerning the use of PGB 
and GBP for CS; 
• Literature review 
Part two  
Compile evidence on the efficacy and AE profile of PGB and GBP when used to treat 
CS, using retrospective clinical data collection; 
• Retrospective study with existing data 
• Questions of AEs, medication experience and perceptions 
• Develop methodology for a randomised clinical trial 
Part three  
Determine the efficacy of PGB and GBP when used to treat CS and whether one is 
superior to the other. Determine the frequency and severity of AEs when patients are 
treated with PGB and GBP for CS. Explore if personality traits have any effect on 
treatment outcomes. 
• A double-blind, randomised, cross over clinical trial 
• Sub analysis to examine Health Locus of Control (HLoC) in patients being 
treated with PGB and GBP for CS. 
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This study has received ethical approval from the Townsville Hospital and Health 
Service District Human Research Ethics Committee and the James Cook University 
Human Research Ethics Committee (appendices) 
Further information on methodology can be found within chapters, however a synopsis 
is given below. 
Part One: A review of the literature regarding current evidence on the use of 
PGB and GBP for CS.  
This comprehensive background search forms the foundations of this research and 
provides information on effect measures and expected outcomes. 
Studies included in this review were identified using electronic searching of the 
PubMed/Medline, CINAHL and Cochrane databases. Key search and MeSH terms 
were used. Search terms were not used individually, but in combination in order to 
achieve focused results. Combinations include “Pregabalin AND Sciatica”, Gabapentin 
AND Sciatica” and “Pregabalin AND Gabapentin AND Sciatica”. 
The focus is on publications in English and studies carried out in humans. Further 
refinement includes studies limited to describing safety, efficacy and/or tolerability of 
PGB and/or GBP in CS. Studies analysing other NP conditions in combination with 
sciatica were considered. Articles exploring PGB and GBP as combination treatments 
with non-opioid analgesics were excluded as well as trial protocols and post-surgical 
populations.  
A reviewer screened all relevant titles and abstracts and excluded papers not relevant 
to this research. Another reviewer independently evaluated the full reports for 
eligibility. Discussion and consensus were used to resolve differences in assessment. 
To identify potential articles missed by the electronic search, the bibliographies of the 
identified articles were analysed, and any appropriate article based on title and 
abstract was also retrieved.  
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Part Two: Compile evidence based on retrospective data collection on the 
efficacy and AE profile of PGB and GBP when used to treat CS. 
The method for this section includes accessing retrospective data for a cohort of 
patients with unilateral CS attending a specialist spine clinic. Data were collected as 
part of routine care.  Eligible patients have experienced partial benefit to a pre-existent 
regime containing a first line drug: none had significant AE.  Addition or discontinuation 
of drugs during the study were limited to only GBP. VAS, Oswestry Disability Index 
(ODI) and AE were recorded as markers for efficacy.  
Part Three: Determine the efficacy of PGB and GBP when used to treat CS. Sub 
analysis to examine HLoC in patients being treated with PGB and GBP for CS. 
This prospective, randomised, double-blind, double-dummy cross-over study recruited 
patients over 18 years, with unilateral CS and radiological confirmation of 
corresponding neural compression/irritation. Pregnant women, those with major organ 
disease, creatinine clearance <60ml/min or another neuropathy were excluded.  
Patients continued their pain medication used at study onset and the prior 30 days.  
No drug changes or other pain interventions were permitted throughout the period of 
study. Each drug was titrated to a target dose (GBP: 400-800mg tds, PGB: 150-300mg 
bd) and taken for 8 weeks.  The first drug was then ceased. Cross-over was deferred 
for a 1-week washout period. Drug efficacy was assessed by the VAS, ODI Index and 
HLoC. AEs and psychological functioning were also assessed. Assuming the 
hypothesis that one drug was superior (or both drugs were different), the sample size 
required is n=38 with 80% power and 5% type 1 error rate. Results were analysed via 
intention-to-treat methodology.  
The HLoC sub-study was carried out as part of a randomised controlled trial. The 
adapted HLoC questionnaire was used to assess the participant’s sense of self control 
over his/her own health.  The score for each subsection (internal, chance, external) 
relates to the patient’s belief in the importance of being able to influence their own 
treatment decisions. Pain intensity was measured by VAS and disability level by ODI 
and used as markers for efficacy of medications. 
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1.7 Study Management 
The supervisory team met regularly (every 2-4 weeks) to review the progress, 
outcomes, and conduct of the research project. A progress report was sent to any of 
the supervisors unable to attend the meeting in person. Regular informal 
communication was also conducted to ensure consistency and robustness of the 
project. 
1.8 Expected Outcomes 
• PGB and GBP will reduce pain severity (VAS) when used to treat CS. 
• PGB and GBP will reduce disability severity (ODI) when used to treat CS. 
• Personality traits and quality of life (HLoC) influence treatment outcomes with 
PGB and GBP in CS patients. 
• When compared head to head, a difference exists between PGB and GBP in 
reducing pain severity and disability severity. 
• When compared head to head, a difference exists between PGB and GBP in 
the frequency and severity of AEs.  
1.9 Thesis structure and outline 
This research investigates two common pharmacological treatments for CS, namely 
PGB and GBP. The work is presented as a series of published papers in international 
and national journals. The thesis consists of seven chapters each with a different 
focus. The seven chapters are as follows: 
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Figure 1.1 Thesis structure 
 
Chapter 1 provides the context of the research. Justification for the research is outlined 
by defining NP and CS, describing the burden it places on society and outlining 
current treatments options and their AE profile. The significance of the research is 
described in terms of unmet needs. A rationale is given for the study design, which is 
based on the ability to detect superiority of either PGB or GBP. The clinical trial 
design is in line with internationally recognised principles for the conduct of clinical 
trials and was conducted in accordance with Good Clinical Practice (GCP) principles.  
Chapter 2 investigates the literature. This review highlights a key conclusion that PGB 
and GBP for CS have been under-explored. Work in this chapter has been published 
in the Journal of Clinical Neuroscience, 2016, volume 26 pages 1-7. DOI 
10.1016/j.jocn.2015.05.061 
Chapter 3 investigates GBP treatment in a CS population attending a specialist spine 
clinic. This study highlights AEs and efficacy of GBP and provides useful information 
for the design and methodology for the clinical trial. This study has been published in 
the journal Pain Medicine, 2016, April, pages 1-5. DOI  10.1093/pm/pnw052 
Chapter 1
• Introduction and Background.
Chapter 2
Chapter 3
•Review: Pregabalin and Gabapentin for the Treatment of Sciatica.
•Gabapentin Super-Added to a Pre-Existent Regime containing Amitriptyline for Chronic Sciatica.
Chapter 4
• Pregabalin versus Gabapentin in the Treatment of Sciatica: A Study Protocol for a Randomised, Double-Blind and Cross-Over 
trial (PAGPROS).
Chapter 5
Chapter 6
• Effect of Gabapentin versus Pregabalin on Pain Intensity in Adults for Treatment of Chronic Sciatica: A Randomised Clinical 
Trial.
• The Relationship between Health Locus of Control and Anti-Neuropathic Drug Efficacy in Patients with Chronic Sciatica.
Chapter 7
•Overall Discussion and Conclusions.
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Chapter 4 investigates study design and methods, and address issues of 
recruitment and ethics, following CONSORT guidelines for the reporting of clinical 
trials. This study has been published in the journal BMC Trials, January 2019, 19:21 
https://doi.org/10.1186/s13063-017-2400-y. 
Chapter 5 investigates the head-to-head comparison of PGB and GBP in a randomised 
controlled trial. This study has been published in JAMA Neurology, published online 
October 15, 2018. http://Doi:10.1001/jamaneurol.2018.3077. 
Chapter 6 investigates the relationship between treatment outcomes and personality. In 
this chapter, a HLoC survey is analysed to explore a relationship to medication 
effectiveness. This study has been submitted to the Pain Medicine journal. 
Chapter 7 provides an overall discussion, draws conclusions and provides 
recommendations based on the findings of this research. 
The style of the thesis is structured according to the James Cook University (JCU) 
reference style (American Psychological Association, APA 6) preferred by the College 
of Medicine and Dentistry. The JCU allows published journal papers to be included 
in the thesis. The inclusion of publications in this thesis means that different 
publications may contain the same or similar descriptions of concepts, test procedures 
and findings. Different referencing styles were employed as required by the journals 
in which the papers were published. Similarly, the spelling of some words might not 
be consistent throughout the thesis. 
1.10 Summary 
This thesis will explore the gap in knowledge that is needed for more effective and 
improved treatment options for CS and provide an overview of the most current 
treatment option between PGB or GBP. A randomised, double-blind and cross-over 
clinical trial was used to test the efficacy of both PGB and GBP in CS, with the results 
reported within chapter 5 of this dissertation.  
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Chapter 2 Review: Pregabalin and Gabapentin for the 
Treatment of Sciatica 
‘The scientific method actually correctly uses the most direct evidence as 
the most reliable, because that’s the way you are least likely to get led 
astray into dead ends and to misunderstand your data’ 
Aubrey de Grey (1963–) 
2.1 Background 
Pain experienced by patients is a very broad term and to research in its entirety is 
beyond the scope of this work. Different mechanisms including social, mechanical and 
behavioural contribute to a dimension of experienced pain. However, if the 
experienced pain is caused by a specific condition such as chronic sciatica (CS), we 
can be more precise and robust in researching medications to alleviate this pain. 
While undertaking a preliminary project on pain generally, a common theme started to 
emerge. The drugs pregabalin (PGB) and gabapentin (GBP) were captured in most of 
our data with a varied and unequal prescription to patients. On further exploration, both 
medications were being utilised for the same indication of CS. A brief snapshot of the 
non-parametric use of these two drugs for sciatica prompted further research. 
However, before this could proceed a review of the literature was needed. 
Chapter 2 of this thesis, entitled “Review: Pregabalin and Gabapentin for the 
Treatment of Sciatica” is based on the manuscript published in the Journal of Clinical 
Neuroscience. The paper is inserted into this thesis with minor modifications. Only 
the formatting of section sub-headings and numbering of tables and figures have been 
modified from the original publication to match the thesis format. The referencing of 
the paper is retained in the original journal style. 
Robertson K, Marshman L, Plummer D. (2016). Review: Pregabalin and 
Gabapentin for the Treatment of Sciatica. Journal of Clinical Neuroscience.  26: 
1-7. DOI: 10.1016/j.jocn.2015.05.061 
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2.2 Abstract 
Whilst PGB and GBP are both used to treat NP, their relative role in CS is unclear. 
Our aim was to extensively review the relative role of PGB and GBP in treating sciatica 
and specifically CS. The efficacy, adverse event (AE) profile and cost of PGB and GBP 
in NP states were reviewed with special reference to CS. N=11 articles matched the 
criteria: n=7 systematic reviews, n=1 retrospective cross-sectional study, n=1 placebo-
controlled-crossover study, n=1 randomized placebo-controlled double-blind study 
and n=1 case report. GBP and PGB appeared to demonstrate comparable efficacy 
and AE. However, the amount and quality of evidence was low, and only indirect 
comparisons were available.  Importantly, no direct ‘head-to-head’ study existed.  
Globally, costs varied widely (by up to x31) and unpredictably (PGB cheaper than 
GBP, or vice versa).  Formulary regulator rulings were globally disparate: however, 
many exclusively favoured the more expensive drug (whether GBP or PGB).  No 
studies assessed PGB-GBP interchange. Weak evidence suggests that efficacy and 
AE with GBP and PGB are probably similar: however, firm conclusions are precluded.  
Despite weak data, and having cited minor titration but definite cost advantages, NICE-
UK favoured PGB over GBP.  However, globally, costs vary widely and unpredictably: 
paradoxically, many Formulary regulators exclusively favour the more expensive drug 
(whether GBP or PGB).  Given that no evidence supports unhindered PGB-GBP 
interchange, neither drug should probably be favoured.  Prospective ‘head-to-head’ 
studies are urgently required to provide robust evidence-base for relative GBP/PGB 
use in CS. 
2.3 Introduction 
Anecdotally, both GBP and PGB have been widely used to treat NP states, including 
CS.  However, the efficacy and AEs of GBP and PGB for the treatment of patients with 
CS have not been firmly established. Only two limited specific reviews exist. The first 
emanates from the UK National Institute for Health and Clinical Excellence (NICE-UK) 
(1). The second is a recent systematic review, and meta-analysis, for the 
pharmacological treatment of sciatica by Pinto et al. (2).  Both could only make indirect 
comparisons between GBP and PGB, whilst the review of Pinto et al. was based on 
one study for each drug, both trials failed to satisfy accepted criteria for being a high-
13 
 
quality design (2, 3). No review appears to have sufficiently examined the AEs and 
quality-of-life differences between the different preparations.   
Sciatica or sciatic neuralgia, a common form of lumbosacral radiculopathy, is 
characterised by low back pain which radiates to the leg and which may be 
accompanied by sensory loss, motor weakness and/or reflex abnormalities. Sciatica 
is a symptom defined as well-localised leg pain, with a sharp, shooting or burning 
quality that approximates to the dermatomal distribution of the sciatic nerve down the 
posterior lateral aspect of the leg (2).  It is often associated with numbness or 
paraesthesia in the same distribution but typically extends beyond the limits of 
perceived pain in either a dermatomal or sclerotomal anatomical fashion (4, 5). The term 
“sciatica” is used by clinicians in different ways; some refer to any leg pain referred 
from the back as sciatica; others prefer to restrict the term to pain originating from the 
lumbar nerve root. Others believe sciatica is a form of 'neuropathic' pain caused by 
compression or irritation of the roots or nerves that comprise the sciatic nerve (2,6). CS 
is sciatica lasting at least 3 months. These definitional inconsistencies potentially 
confound analysis within and between studies.  
A substantial proportion of patients with CS have persistent pain for two years or longer 
(2), which contributes to increased absence from employment and increased 
applications for work cover compensation. The annual prevalence of CS is estimated 
to be between 1.6% and 43% (6). While guidelines provide clear and generally 
consistent recommendations for prescribing analgesics to treat non-specific low back 
pain, often the same guidelines are applied for the dissimilar diagnosis of CS, and 
more recently, non-evidenced based use of either PGB or GBP. 
Chronic low back pain per se can often be managed with simple analgesic regimen 
that include paracetamol, non-steroidal anti-inflammatory agents (e.g. ibuprofen), or 
opioid analgesics (e.g. codeine or tramadol). CS, however, like most NP states, is 
often resistant to simple analgesic regimens (2, 6). NP is typically managed by super-
adding anti-convulsant drugs onto basic analgesic regimes: the drugs most commonly 
used are GBP or PGB. CS is therefore increasingly being treated with super-added 
GBP or PGB (2, 6). Both are analgesics derived from Gamma-Aminobutyric Acid 
(GABA) that modulate the calcium-channel subunits, possibly decreasing 
neurotransmitter release that occurs in CS (2 ,6).  
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It is important to note that at some stage in the patient's management of CS, either 
PGB or GBP may constitute the next-line treatment offered: either as an alternative to 
surgery (with its greater risks), or as a penultimate step before committing towards 
surgery (with its greater risks). That is, patients may be offered either drug at a stage 
in their management where response to standard first-line analgesics has proven 
insufficient. However, the precise role of PGB or GBP in CS has been surprisingly 
under-explored (2, 7). In consequence, individual prescribers have defaulted to a 
position of equipoise pending the outcome of direct, high quality research to rationalize 
the use of PGB or GBP in the treatment of CS (7).    
The aim was to review the utility (i.e. efficacy, AE profile and cost) of PGB and GBP in 
NP states with special reference to CS.    
2.4 Methods 
Studies to be included in the review were identified using electronic searching of the 
PubMed/Medline, CINAHL and Cochrane databases from the earliest records to 14th 
March 2015. Key search and MeSH terms used included “Pregabalin”, “Gabapentin”, 
“Sciatica”. Terms were selected based on the keywords and the title in the review 
which included the synonym’s radiculopathy, nerve root compromise or compression, 
nerve root pain or entrapment, lumbosacral radicular syndrome, or pain defined as 
radiating below the knee. Terms were not used individually, but in combination in order 
to achieve focused results. Combinations included “Pregabalin AND Sciatica”, 
Gabapentin AND Sciatica” and “Pregabalin AND Gabapentin AND sciatica”. 
The identified citations were refined to publications in English and studies carried out 
in human. Further refinement included studies limited to describing safety, efficacy 
and/or tolerability of PGB and/or GBP in CS. Studies that analysed other NP conditions 
in combination with sciatica were also included. Articles exploring GBP and PGB as 
combination treatments were excluded as well as trial protocols and post-surgical 
populations.  
One reviewer screened all relevant titles and abstracts and excluded irrelevant papers. 
Two reviewers independently evaluated the full reports for eligibility. Discussion and 
consensus was used to resolve differences in assessment. To identify potential articles 
15 
 
missed by the electronic search, the bibliographies of the identified articles were 
analysed and any appropriate article based on title and abstract were also retrieved.  
Decisions to include papers in this review did not depend on their quality. The goal 
was to present all published studies that met our inclusion criteria regardless of the 
design type and quality.  
Formal meta-analytic methods were precluded because of the broad scope of adverse 
events and painful symptoms, the variety of measures used to assess AEs, and the 
different study definitions of pain. This review is a quantitative and semi qualitative 
synthesis of the relevant, representative, and evidence-based literature. 
2.5 Results 
Thirteen studies were identified in the initial search with 2 studies being excluded due 
to irrelevance (8, 9). Eleven studies were included in the literature review that examined 
the safety, efficacy and/or tolerability of PGB and GBP for patients with sciatica. All 
eleven studies were included in this review. The studies included in the review were 
seven systematic reviews, one retrospective cross-sectional study, one placebo 
controlled crossover study, and one randomized placebo-controlled double-blind study 
and one case report. (Table 2.1) 
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Table 2.1 Studies included in the literature review 
STUDY DESIGN OBJECTIVES FINDINGS 
Sumracki N et al 
(2012) (15) 
 
Randomised, double-blind, 
placebo-controlled, three-way 
crossover study in unilateral 
sciatica 
Tolerability and efficacy 
of Minocycline and 
Pregabalin 
Although not significant once adjusting the P-value, the 28% 
(95% CI 0% to 56%) reduction of hyperalgesia in the 
affected leg prior to intradermal capsaicin by single oral dose 
minocycline is a novel finding that glial attenuation may be 
anti-hyperalgesia in humans. 
Moore RA et al 
(2011) (8) 
Systematic review of 
randomized double-blind 
studies in chronic neuropathic 
pain and fibromyalgia 
Tolerability and efficacy 
of Gabapentin 
compared to placebo 
Gabapentin was superior to placebo in 14 studies with 43% 
improving with Gabapentin and 26% with placebo; the NNT 
was 5.8 (4.8 to 7.2).  
Wiffin PJ et al 
(2010) (9) 
Systematic review of 
randomized trials for acute and 
chronic pain 
Tolerability and efficacy 
of Gabapentin 
compared to placebo 
The study in acute post-operative pain showed no benefit for 
Gabapentin compared to placebo for pain at rest. In chronic 
pain, the NNT for improvement in all trials with evaluable 
data is 4.3 (95% CI 3.5 to 5.7). Forty two percent of 
participants improved on Gabapentin compared to 19% on 
placebo.  
Finnerup NB et al 
(2010) (10) 
Systematic review of 
randomized, double-blind 
placebo controlled trials for 
neuropathic pain 
Pharmacological 
management in 
neuropathic pain.  
Tricyclic antidepressants, serotonin noradrenaline reuptake 
inhibitors, the anticonvulsants Gabapentin and Pregabalin, 
and opioids are the drug classes for which there is the best 
evidence for a clinical relevant effect.  
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Straube S et al 
(2012) (13) 
Systematic review of double 
blind trials compared with 
placebo for established acute 
postoperative pain in adults 
Efficacy and tolerability 
of Single dose oral 
Gabapentin and 
placebo 
At least 50% pain relief over 6 hours was achieved by 15% 
with Gabapentin and 5% with placebo.  Significantly fewer 
participants needed rescue medication within 6 hours with 
Gabapentin than with placebo. About one third of 
participants reported adverse events with both Gabapentin 
and placebo. No serious adverse events occurred with 
Gabapentin. 
Wiffen PJ et al 
(2005) (11) 
Systematic review of 
randomized controlled trials for 
acute and chronic pain 
Anticonvulsant drug’s 
efficacy and tolerability  
 
The only placebo-controlled study in acute pain found no 
analgesic effect of Sodium Valproate. Three placebo-
controlled studies of Carbamazepine in trigeminal neuralgia 
had a combined NNT (95% confidence interval (CI)) for 
effectiveness of 2.5 (CI 2.0 to 3.4). A single placebo-
controlled trial of Gabapentin in post-herpetic neuralgia had 
an NNT of 3.2 (CI 2.4 to 5.0). 
Grice GR et al 
(2008) (18) 
 A Case report on sciatica A report of Gabapentin 
usage for 2 patients. 
The first was a patient was treated with many alternative 
drugs and, he was then prescribed Gabapentin his pain 
substantially improved, even after the first dose. The second 
patient was a 68-year-old treated with Gabapentin 100 mg at 
bedtime. Pain improved rapidly.  
Gore M et al 
(2007) (12) 
Retrospective cross-sectional 
study about painful peripheral 
neuropathic disorders 
Usage patterns of 
common drugs for 
painful neuropathic 
disorders (PND’s) 
Use of medications with clinically demonstrated efficacy in 
PNDs was high. Average daily doses of select neuropathic 
pain-related medications among PND patients were lower 
than those recommended for neuropathic pain. The use and 
doses of evidenced-based neuropathic pain-related 
medications was low, and lower than the use of NSAIDs (a 
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medication class with no proven efficacy for PNDs) in each 
group, suggesting possible sub-optimal neuropathic pain 
management among these patients. 
Pinto et al (2012) 
(2) 
Systematic review and meta-
analysis of drugs for treatment 
of sciatica 
Efficacy and tolerability 
of drug treatments for 
sciatica. 
NSAIDs showed low evidence of efficacy (P<0.06). No 
NSAIDS displayed better effects than the other. 
Corticosteroids showed significant effects on pain (P<0.01). 
Gabapentin showed great efficacy compared to placebo 
(P<0.01), Topiramate showed no better effects than placebo. 
Combo of antidepressant + opioid had no significant effect 
compared with placebo. 
For all included studies, the median adverse events were 
17% for active drugs and 11% placebo.  
Burke SM et al 
(2010) (14) 
 
Randomized double-blind 
placebo controlled study of 
Lumbar Discectomy 
Tolerability and efficacy 
of Pregabalin 
compared to placebo 
The decrease in VAS score at 3 months was greater in 
patients who received Pregabalin than those who received 
placebo. The Roland Morris disability score at 3 months was 
less in patients who received Pregabalin. Pregabalin 
administration was associated with greater pain tolerance 
thresholds in both lower limbs compared with placebo at 24 
hours postoperatively. 
Moore RA et al 
(2009) (16) 
 
Systematic review of 
randomised double-blind trials 
in acute and chronic pain 
Efficacy and tolerability 
of Pregabalin 
There was no clear evidence of beneficial effects of 
Pregabalin in established acute postoperative pain. No 
studies evaluated Pregabalin in chronic nociceptive pain, like 
arthritis.  
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2.5.1 Efficacy: Gabapentin 
2.5.1.1 Sciatica 
The use of GBP to reduce pain has been extensively covered in systematic reviews. 
In a review and meta-analysis involving 23 studies for the drug treatment of sciatica, 
GBP showed greater efficacy in pain reduction compared to placebo in participants 
with sciatica (mean diff -26.6 (-38.3 to-14.9) (2).  
2.5.1.2 Other Conditions 
Additionally, a systematic review of 29 studies involving 3571 patients was 
performed in 2011 to analyse the effects of GBP in chronic NP and fibromyalgia. 
GBP was superior to placebo in 14 studies with 43% of patients improving with GBP 
and 26% with placebo; the number needed to harm (NNH) was 5.8 (4.8 to 7.2). 
Furthermore, using the IMPACT definition of substantial benefit, GBP was superior 
to placebo in 13 studies with 31% of patients improving with GBP compared to 17% 
with placebo (10). 
In another systematic review of GBP use in acute and chronic pain, the study 
showed no benefit for GBP compared to placebo for pain at rest (11). In chronic pain, 
the NNT for improvement in all trials with evaluable data is 4.3 (95% CI 3.5 to 5.7) 
with 42% of participants improving on GBP compared to 19% on placebo (11). A 
larger systematic review examining 174 trials in NP showed that GBP had an overall 
number needed to harm (NNH) of 32.5 (18-222) when used as a treatment for a 
variety of NP disorders (12).  
An earlier review for acute and chronic pain reported a single-placebo controlled trial 
of GBP in post-herpetic neuralgia had an NNT of 3.2 (CI 2.4 to 5.0). In the same 
review, for diabetic neuropathy NNT for effectiveness was 3.8 (CI 2.4 to 8.7) for the 
population treated with GBP (13). 
In light of this evidence for GBP’s utility, a cross-sectional study into painful 
neuropathic disorders found that average daily doses for GBP were commonly 
suboptimal for pain management among these patients (14). 
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However, for most of these systematic reviews, even when restricting inclusion to 
randomised, double-blind studies, the review incorporated a majority of trials with 
either an unclear or high risk of bias due to design flaws, differing measured 
outcomes, dosage variation and inconsistent conditions being treated.  
2.5.1.3 Single Dose Gabapentin 
Single-dose GBP was explored in a review consisting of 4 unpublished studies for 
acute postoperative pain in adults (15). At least 50% pain relief over 6 hours was 
achieved by 15% of patients with GBP 250 mg and 5% with placebo; giving a Risk: 
Benefit of 2.5 (95% CI 1.2 to 5.0) and an NNH of 11 (6.4 to 35). Also noteworthy 
was that significantly fewer participants needed rescue medication within 6 hours 
with GBP 250 mg than with placebo (15).  
The conclusions were that GBP appears to provide high level pain relief in about a 
third of people who take if for NP. Conversely, over half of those treated with GBP 
do not report worthwhile pain relief. Overall, evidence for using this drug in some 
conditions is low, which leaves the question as to why GBP works under some 
circumstances but not others. This finding precludes us confidently concluding that 
it actually works or not when treating patients with sciatica (2, 10). 
2.5.2 Efficacy: Pregabalin 
The reduction of neuropathic and sciatica pain has been less explored for PGB 
compared to GBP. 
2.5.2.1 Sciatica 
The use of PGB to reduce pain and time to loss of response (LOR) was reviewed in 
a meta-analysis involving 23 studies for the drug treatment of sciatica. Most patients 
with chronic lumbosacral radiculopathy responded to PGB therapy; however, time 
to LOR did not significantly differ between PGB and placebo (2). 
A randomised, double-blind placebo controlled trial examined the effect of PGB on 
pain following lumbar discectomy in 40 participants. The decrease in pain score was 
greater at 3 months for the patients treated with PGB compared to placebo (p=0.08). 
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PGB was associated with greater pain tolerance thresholds in both lower limbs 
compared with placebo at 24 hours postoperatively (16). 
In a randomised, double-blind, placebo-controlled, three-way cross-over study of 18 
patients with unilateral sciatica, PGB did not reduce capsaicin-induced spontaneous 
pain. Importantly however, the design of the study was primarily focused on the 
activity of an alternative drug, Minocycline, in unilateral sciatica (17).  
2.5.2.2 Other Conditions 
A systematic review involving 174 studies of various NP conditions suggested that 
PGB is a member of a class of drugs in which there is best evidence for clinical 
effect. When the data was pooled, PGB displayed a number needed to harm (NNH) 
of 10.6 (8.7-14) which was approximately 3 times less than its comparator agent 
GBP. This tends to indicate that PGP has a higher adverse event rate (12). 
A large systematic review which studied more than 70,000 participants concluded 
that there was no clear evidence of beneficial effects of PGB for acute pain. No 
studies included in the review explored chronic pain. The best (lowest) NNT for each 
condition for at least 50% pain relief over baseline (substantial benefit) for PGB 
compared with placebo was 3.9 (95% confidence interval 3.1 to 5.1) for post herpetic 
neuralgia, 5.0 (4.0 to 6.6) for painful diabetic neuropathy, 5.6 (3.5 to 14) for central 
NP, and 11 (7.1 to 21) for fibromyalgia (18). 
Overall, the reviewed studies failed to satisfy accepted criteria for being a high-
quality trial (3) and led to a generalised conclusion that individualisation of treatment 
with PGB is needed to maximise pain relief and minimise adverse effects. Patients 
with niche indications or where there is a contraindication to GBP AEs are often 
being prescribed PGB. 
2.5.3 Adverse Events – Gabapentin 
AEs in populations administering GBP or PGB were frequent, but mostly tolerable. 
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2.5.3.1 Sciatica 
A large review and meta-analysis reported 2 from 25 patients treated with GBP 
experienced an AE including dizziness, somnolence, chest pain, fainting, dry mouth, 
constipation, weight increase, headache and peripheral oedema. However, the 
numbers of AEs were fewer compared to PGB. In this study, patients allocated to 
the placebo control arm reported no AEs (2).  
2.5.3.2 Other Conditions 
A study GBP for treating chronic NP and fibromyalgia, reported that 12% of patients 
withdrew from the study because of AEs when the dose was 1200mg or more. This 
compares with 8% for placebo giving a risk ratio of 1.4 (1.1 to 1.7). Somnolence, 
drowsiness, sedation, peripheral oedema and ataxia were the most common 
complaints from participants receiving GBP. All-cause withdrawals occurred in 20% 
of participants being treated with GBP compared to 19% receiving placebo (risk ratio 
1.1, 0.9 – 1.2), and patients experiencing at least one AE was experienced by 66% 
of GBP patients and 51% on placebo (risk ratio 1.3, 1.2-1.4)10. Of these mentioned 
AEs, 4% on GBP and 3.2% on placebo were considered to be serious (10). 
Another review examined the utility of GBP in acute and chronic pain, with the 
authors reporting the NNH for each episode of major harm from GBP usage. Major 
harm was considered to be any effects that lead to participants withdrawing from the 
study. The resultant NNH for major harm was not statistically significant, however 
for minor harm, the authors report a NNH of 3.7 (2.4 to 5.4). The most common AEs 
were dizziness (24%), somnolence (20%), headache (10%), diarrhoea (10%), 
confusion (7%) and nausea (8%) (11). 
2.5.3.3 Single dose Gabapentin 
Single dose GBP was compared to placebo for established acute postoperative pain 
in adults. A low-quality review which included four unpublished studies showed 28% 
of patients taking GBP experienced at least one AE compared to 32% for placebo. 
The relative risk for treatment with GBP was 0.91 (95%CI 0.66-1.3). No serious AEs 
were reported with GBP use; however, there was a report of “heart arrest” occurring 
one day after study completion. Withdrawals from the study were limited, with only 
3/370 participants receiving GBP leaving the study due to fever (15). 
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2.5.4 Adverse Events – Pregabalin 
2.5.4.1 Sciatica 
The AEs of PGB were reported in a randomised double-blind placebo controlled 
study when used to treat pain following lumbar discectomy. Visual disturbances 
occurred in 2/18 patients in the PGB group, however these were self-limiting and 
resolved within 4 hours in all cases. Somnolence and dizziness were also reported 
in patients receiving PGB (16).  
In a small randomised double-blind cross-over study where PGB was used as a 
control, 14 of the 18 participants (78%) experienced AEs following PGB treatment. 
These events included dizziness, nausea and tiredness. However, these events 
were reported retrospectively at the end of the study (17). 
A large systematic review and meta-analysis which included studies using 
treatments for sciatica reported that 31 from 110 patients allocated PGB 
experienced at least one AE including dizziness, somnolence, chest pain, fainting, 
dry mouth, constipation, weight increase, headache and peripheral oedema.  A 
greater number of AEs were reported with the usage of PGB (2). Additionally, the 
systematic review found that patients allocated to the placebo control arm, did not 
report a single AE (2). 
2.5.4.2 Other Conditions 
Conclusions about the frequency of AEs associated with PGB could not be reported 
in a study for acute and chronic pain, because these events were not recorded in all 
studies. Consequently, the authors had to perform dose-dependent adverse event 
analysis with the results showing there is no link between a higher dose and greater 
adverse outcome. The only reported AEs were somnolence and dizziness (18).  
The rate and type of reported AEs varied substantially between drugs and between 
trials of the same medication. 
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2.5.5 Costing and National Formulary Listing – Pregabalin and 
Gabapentin 
The cost of each drug varied widely between countries (Table 2.2): e.g., costs for 
GBP varied by a factor of 31 between the UK and USA (from $8.43 to $263.32).  
The cost of each drug also varied unpredictably between countries (Table 2.2): e.g. 
in Australia, PGB ($51.71 for 56 150mg capsules) was more expensive than GBP 
($29.13 for 100 400mg capsules), whilst in New Zealand GBP was more expensive 
than PGB.  Moreover, costs for both drugs were markedly more expensive (by a 
factor of 6 for GBP) in New Zealand compared to Australia ($173.56 for GBP and 
$115.51 for PGB).     
Paradoxically, most nations (4/7) for which data could be easily obtained solely 
favoured the more expensive drug (whether GBP or PGB) (Table 2.2).  For example, 
New Zealand and Singapore listed only GBP, whilst Australia and Europe listed only 
PGB: in all cases, the more expensive drug (Table 2.2). By contrast, USA, UK and 
Canada listed both drugs.  However, the criteria required to obtain GBP in USA and 
Canada were more stringent than with PGB: thus, PGB was still favoured in these 
countries.  Interestingly, in the USA, where both drugs were listed, PGB and GBP 
were both comparable in cost (PGB: $221.86 for 56 150mg capsules compared to 
GBP: $263.32 for 100 400mg capsules): a similar situation prevailed in Canada.  
However, whilst cost comparability between PGB and GBP also prevailed in Europe, 
only PGB was listed in Europe (22).  Finally, whilst both PGB and GBP were listed 
in some UK hospitals, PGB was markedly more expensive (by a factor of 13) than 
GBP.  
2.6 Discussion 
Only 2 limited specific reviews which account for the role of PGB or GBP in CS exist.   
The first emanates from NICE-UK which recommended a variety of treatment 
modalities for the relief of pain associated with neuropathic conditions (1). NICE-UK 
guidelines state that there is evidence for the efficacy of PGB and GBP for treating 
NP disorders, including CS: however, “adverse effects should be discussed with 
each patient, and weighed against potential benefits”.  Whilst both PGB and GBP 
were considered efficacious, NICE-UK nevertheless favoured PGB over GBP for 3 
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main reasons: 1) lower number needed to treat (NNT) values from meta-analysis 
comparisons, 2) simpler dosing and titration regime with PGB and 3) cost-
effectiveness over GBP.  
However, when considering NICE-UK guidelines, it is important firstly to note that 
they were derived only from indirect comparisons of weak power.  Furthermore, NNT 
values were quoted which are open to bias, and for which confidence intervals 
cannot be reliably determined.  Regarding dosing, the regime for PGB – whilst 
simpler (i.e. twice daily dosing) – is not majorly different from GBP (thrice daily).  
Furthermore, whilst GBP should be titrated with delayed dosage increments (e.g. 4 
days), many now also consider that, in order to offset AEs, PGB should similarly be 
introduced in “low and slow” incremental fashion.  On this view, the advantages of 
PGB titration seem exaggerated.  Finally, it is important to note that costs for either 
PGB or GBP vary widely and unpredictably globally (Table 2.2).  Thus, while NICE-
UK considered PGB more cost effective, the converse is true in other countries: e.g. 
GBP is substantially cheaper in Australia than PGB.  Despite the latter, and 
somewhat surprisingly, only PGB is subsidised on the Australian PBS: this 
presumably reflecting the influence of NICE-UK guidelines.    
The second, and most recent, systematic review, and meta-analysis concerning 
drug treatment per se for CS is that of Pinto et al. (1). However, only one study each 
for GBP and PGB was included. The appraisal and conclusions of the study 
highlighted the low quality of extant trials, and the fact that the best primary 
management for CS remained unclear: especially regarding GBP and PGB. The 
review of Pinto et al. showed significant efficacy for GBP without any comment on 
PGB.  Our review, by contrast, examines 11 studies in which PGB or GBP were 
used to treat NP including CS.    
Inconclusive evidence for either PGB or GBP in the treatment of CS and NP 
conditions is reflected worldwide by significant disparity in the rulings of individual 
Formulary regulators. For example, GBP is currently available on the PBS in 
Australia and some hospitals in the UK only for epilepsy: it is not listed for NP. PGB, 
by contrast, is subsidised on the Australian PBS for NP. The Food and Drug 
Administration (FDA) in the USA, along with Health Canada, have adopted similar 
reimbursement criteria to that of the Australian PBS: notwithstanding, both GBP and 
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PGB can be accessed in the USA and Canada via special access schemes (if 
patients satisfy stringent criteria for NP).  In marked contrast, GBP is listed for use 
in both partial seizures and NP throughout Europe.  The rulings of Formulary 
regulators have therefore been inconsistent, and dependent upon the individual 
body.  
Our review has confirmed the absence of any adequately powered direct ‘head-to-
head’ trial comparing GBP and PGB.  Formulary regulators have therefore globally 
used indirect comparisons to inform listing decisions. Such indirect comparisons 
possess numerous limitations: including differing patient demographics, primary 
outcomes and pain measurement scales. Based on NICE-UK guidelines, weak 
evidence suggests that efficacy and AE profiles of PGB and GBP in CS are probably 
similar: however, firm conclusions are necessarily precluded.  NICE-UK noted, as 
one factor in favouring PGB over GBP, that PGB had distinct pharmacokinetic 
advantages: including higher bioavailability, more rapid absorption and increased 
binding affinity.  However, such factors are secondary, and had only gained 
eminence owing to a lack of firm evidence for primary factors (i.e. efficacy and AE 
profiles).    
The lack of firm evidence for the use of either PGB or GBP in CS has, in 
consequence, permitted global inconsistency in the rulings of individual Formulary 
regulators regarding drug preference.  Given that NICE-UK guidelines were 
ultimately largely influenced by cost considerations, one might have expected that 
similar considerations would also account for the wide disparity found in Formulary 
regulator rulings.   However, paradoxically, most countries for which data could be 
easily obtained have solely favoured the more expensive drug (whether GBP or 
PGB) (Table 2.2). Some Nations (UK, USA and Canada) appear to have accepted 
a degree of equipoise, in agreement with current evidence, and have listed both 
drugs.  Particularly in the UK, free interchange between PGB and GBP is therefore 
also possible.  However, whilst USA and Canada listed both drugs, the criteria 
required to obtain GBP are more stringent than with PGB: thus, PGB is still favoured 
in these countries.   In marked contrast, free interchange between PGB and GBP 
has become thwarted in Australia, New Zealand, Europe and Singapore.  Whilst 
NICE-UK noted cost effectiveness to secondarily justify a bias toward PGB, cost 
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cannot explain the Formulary regulator rulings in these countries where solely the 
more expensive drug was listed.  
In Australia, the recent addition of PGB to the PBS for neuropathic pain (2013) has 
created a conflict in that some long-standing users of GBP, who were previously 
controlled on GBP, were subsequently forced to either incur greater costs, or to 
switch to PGB (with, potentially less utility). The Australian Pharmaceutical Benefits 
Advisory Committee rejected applications to subsidise GBP for the treatment of 
neuropathic pain on the grounds of lack of evidence in the proposed population (i.e. 
clinical trial data did not reflect the population covered by the proposed PBS 
restriction) and uncertain cost-effectiveness in this patient group.  However, 
prescribing authorities in Europe appear to have taken a different view (Table 2.2).   
Table 2.2 National Formulary Regulator rulings and costs across nations.   
Country Gabapentin Pregabalin 
Australia (22) NL  
($29.13) 
L 
($51.71) 
New Zealand (23,24) L 
($173.56) 
NL 
($115.51) 
Canada (25,26) L 
($110.32) 
L 
($140.01) 
Europe (19,27)  NL 
($147.32) 
L 
($182.76) 
USA (28,29) L 
($263.32) 
L 
($221.86) 
Singapore (30,31) L 
($174.06) 
NL 
(not available) 
UK (32,33) L 
($8.43) 
L 
($113.31) 
Abbreviations: L listed, NL not listed for NP 
Currency: $US 
*Price is reflective of Pregabalin 150mg capsules quantity 56 and Gabapentin 400mg capsules 
quantity 100. 
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NB: Listing generally equates with favoured, that is, more difficult to obtain the “not listed” drug. In 
some countries e.g. (Australia), this means that the listed drug is subsidised and that not listed drugs 
will incur greater cost to the patient. 
 
The SPORT study (20) showed that many patients with CS will spontaneously 
improve in the medium term with non-operative management: every attempt should 
be made to avoid a potentially unnecessary operation.  Given that some patients 
may benefit from either PGB or GBP (but not both), free interchange between PGB 
and GBP should be facilitated and not obstructed (as it is in many countries).  
However, given that no evidence supports unhindered PGB-GBP substitution; free 
interchange should not be forced as has occurred in countries like Australia, where 
many patients have been forced to interchange GBP with PGB.  Based on current 
evidence, neither drug should probably be favoured.   
2.7 Conclusion 
Weak evidence suggests that efficacy and AE with GBP and PGB are probably 
similar: however, firm conclusions are precluded.  Despite weak data, and having 
cited minor titration but definite cost advantages, NICE-UK favoured PGB over GBP.  
However, globally, costs vary widely and unpredictably: paradoxically, many 
Formulary regulators exclusively favour the more expensive drug (whether GBP or 
PGB).  Given that no evidence supports unhindered PGB-GBP interchange, neither 
drug should probably be favoured.  Prospective ‘head-to-head’ studies are urgently 
required to provide robust evidence-base for relative GBP/PGB use in CS. 
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Chapter 3 Gabapentin Superadded to a Pre-Existent 
Regime Containing Amitriptyline for Chronic 
Sciatica 
‘I have found that most people are willing to accept physical pain and 
limitation rather than acknowledge and deal with the mental and/or 
emotional pain that might have caused it.” 
Tobe Hanson 
3.1 Background 
Only 2 previous studies have assessed Gabapentin (GBP) use in chronic sciatica 
(CS): both by the same author, and one from a journal which has since become 
defunct. In all previous studies, participants were required to cease all prior pain 
medication, and were denied any background therapies (some of which had 
probably proven beneficial). Furthermore, the study designs for these studies did 
not permit the full assessment of adverse events (AEs): hence AEs were either not 
reported, or were very brief. 
Chapter 3 of this thesis, entitled “Gabapentin Super-added to a Pre-Existent Regime 
Containing Amitriptyline for Chronic Sciatica” is based on the manuscript published 
in the Journal Pain Medicine. The paper is inserted into this thesis with minor 
modifications. Only the formatting of section sub-headings and numbering of tables 
and figures have been modified from the original publication to match the thesis 
format. The referencing format of the paper is retained in the original journal style. 
Robertson K, Marshman L. (2016). Gabapentin Super-Added to a Pre-
Existent Regime Containing Amitriptyline for Chronic Sciatica. Pain Medicine. 
April:0: pages 1-5. DOI: 10.1093/pm/pnw052 
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3.2 Abstract 
Setting: There is currently a gross lack of evidence base guiding the medical 
management of CS. Only scant previous studies have assessed GBP in CS.  
Extrapolating NICE-UK guidelines, prescribing authorities often insist on trialling 
anti-depressants (e.g. Amitriptyline, AMP) as first-line for neuropathic pain states, 
like CS.  When super-adding second-line agents, such as GBP, NICE-UK 
encourages overlap with first-line agents to avoid decreased pain-control.  No study 
has reflected this practice. 
Objective: Evaluate efficacy and AE of GBP super-added to a pre-existent regime 
containing AMP for CS.     
Subjects and Methods: Prospective cohort of patients with unilateral CS attending 
a specialist spine clinic.  Eligible patients had experienced partial benefit to a pre-
existent regime containing AMP: none had significant AE.  No drugs other than GBP 
were added or discontinued (the latter was considered inequitable) for 3 months. 
Visual Analogue Pain Score (VAS), Oswestry Disability Index (ODI) and AE were 
recorded.   
Results: Efficacy: in 56% (43/77) there were reductions in VAS (5.3±3.6→2.8±2.7, 
P<0.0001) and ODI (42.8±31.1→30.7±25.2, P=0.008).  AE: Eighty-two AE (23 
types) were reported in 53% (41/77). Efficacy was less in those with AE: a trend 
existed for a lesser reduction in VAS (2.0±2.4 v 3.0±2.7, P=0.08) which proved 
significant for ODI (8.1±11.4 v 16.7±18.2, P=0.01).  Thirty-four per cent (26/77) 
discontinued GBP: all within 1 week (i.e. during titration).   
Conclusion: This was the first prospective cohort study of GBP super-added to a pre-
existent regime containing AMP for CS, as per routine clinical practice and NICE-UK 
principles.  Super-added GBP demonstrated further efficacy over the previous 
regime in 56%: however, AE were frequent (53%) and diverse (23 types); and 34% 
abruptly discarded GBP.  Although AE were associated with decreased efficacy, 
37% nevertheless tolerated GBP despite AE. 
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3.3 Introduction 
Neuropathic pain (NP), arising from diverse conditions such as trauma, infection 
degeneration or idiopathic in origin, is one of the most difficult types of pain to treat 
(1). Chronic sciatica (CS: i.e. sciatica present for more than 3 months), due to 
compression or irritation of lumbo-sacral roots, is assumed to represent NP (2, 3).  A 
recent editorial (4), and a systematic review (3), have both highlighted the gross lack 
of evidence base guiding the current medical management of CS.   
Anti-depressants, such as tri-cyclic antidepressants (TCAs: e.g. amitriptyline AMP), 
are widely used to treat NP; including CS.  Based on ‘moderate-quality’ evidence, 
NICE UK reported TCA efficacy over placebo for NP (4). However, based on ‘high-
quality’ evidence, TCAs were also significantly more likely to produce AEs than 
placebo.  Extrapolating NICE-UK guidelines, prescribing authorities (e.g. Australian 
Therapeutic guidelines, ATG) often insist on trialling TCAs first for NP, prior to 
introducing second-line agents.  Limited information, however, is available regarding 
TCA use specifically in CS.  In one rare cross-over study, Nortriptyline – alone, or 
combined with Morphine – demonstrated no significant benefit over placebo (6).   
Anticonvulsant anti-neuropathic agents, such as GBP, are also widely used to treat 
NP; including CS.  Based on ‘moderate-to-high-quality’ evidence, NICE UK noted 
efficacy of GBP over placebo for NP (4).  However, based on ‘high-quality’ evidence, 
GBP – like TCAs – was also significantly more likely to produce AEs than placebo. 
At the time of this study, Australian prescribing authorities (e.g. ATG) recommended 
anti-neuropathic agents as second-line agents for NP, even though NICE-UK did 
not actually favour TCAs over anti-convulsant as first-line agents (or vice versa).  
However, when introducing second-line agents, NICE-UK did encourage “overlap” 
with first-line agents and pre-existent regimes, to avoid decreased pain-control (4).  
In consequence, many patients in routine practice are co-prescribed both AMP and 
GBP in a sequential manner for control of NP or CS.  
Only 2 previous studies have assessed GBP use in CS (5, 6).  However, neither study 
was representative of routine clinical practice: participants were required to cease 
all prior pain medication, and were denied any background therapies.  Whilst 
imperative for pure scientific study, such practice conflicts with routine clinical 
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practice; and is contrary to NICE-UK guidelines as aforementioned.  Moreover, 
study designs did not permit full assessment of the frequency and type AE.  AE were 
also under-reported in the studies reported by NICE-UK when compared to routine 
clinical practice and National Formularies.  
Given methodological problems encountered previously, our study maintained 
representativeness as per NICE-UK guidelines by including background therapies 
(including first-line AMP) with GBP use in CS. In addition, this work faithfully 
recorded the frequency and type of AE, in order to validate and quantify anecdotal 
evidence of considerable AE emanating from routine clinical practice. 
3.4 Methods 
A cohort of patients attending a specialist spine clinic in an Australian public hospital 
were prospectively studied between Dec 2010-Dec 2012.  This coincided with the 
period when only GBP was subsidised by the hospital authority (PGB was not 
available on the Australian Pharmaceutical Benefit Scheme, PBS, until March 2013).   
3.4.1 Inclusion Criteria 
All study participants were over 18yrs old, had unilateral CS for a minimum of 3 
months due to lumbo-sacral root compression proven on MRI.  All were being 
actively considered for surgery: however, consistent with good medical practice, all 
non-operative angles were being explored first.  Furthermore, subsidised GBP was 
only available as second-line treatment after first-line treatment with AMP.  Eligible 
participants were taking paracetamol and non-steroidal anti-inflammatory drugs 
(NSAIDs) as part of a pre-existent regime, in which codeine-based analgesia was 
only taken ‘as required’.  As recommended by the prescribing authority, all patients 
were also taking AMP in low dose (10-50mg) once daily: none, however, had 
suffered significant AE with their pre-existent regime.  GBP was titrated to each pre-
existing regime for 3 months: initially 300mg once daily for 4 days, 300mg twice daily 
for a further 4 days, and thereafter 300mg thrice daily (as per Australian Therapeutic 
guidelines) (7).  Further 300mg increments were tried, as appropriate, in the same 
fashion to optimise efficacy: however, no patient took more than 1.8g per day.  No 
other drugs were added or discontinued during this interval. The VAS, ODI and AE 
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were recorded.  The local HREC approval was obtained for the study and agreed to 
waive individual consent.  
All patients were fully informed of the possible types of AE associated with GBP, as 
listed in the Australian Medicines Handbook (AMH) (8), prior to participation.  As a 
result, all patients who had previously tried, but discarded, AMP because of AE were 
subsequently found to be also disinclined to take GBP.  Because of this, and 
because all other patients were already taking AMP in a pre-existent regime prior to 
specialist clinic referral, it was not possible to obtain a control arm in which either 
AMP or GBP could be prospectively prescribed alone.  It was considered inequitable 
to ask patients to cease a pre-existent regime which had already proven partially 
beneficial (with no reported AE).  AE and outcome measures were routinely 
recorded at regular clinic attendances at 3 monthly intervals. 
3.4.2 Exclusion Criteria 
Patients were excluded if they were taking other anti-depressants, other opiate 
preparations or other anti-convulsant. Patients were also excluded if they had 
previously tried GBP, had chronic renal failure, had an active unstable psychiatric 
condition (including alcoholism), had previously failed spinal surgery, had bilateral 
sciatica or cauda equina syndrome, infection, tumours, malignancy, known 
osteoporosis, significant confounding hip or knee pathology or were pregnant.    
3.4.3 Statistics 
Efficacy was defined as a reduction in VAS and ODI.  Microsoft Excel and IBM SPSS 
version 19 were used to analyse data. Data was checked for normality and 
appropriate parametric or non-parametric tests performed. Baseline characteristics, 
reduction of pain and ODI scores were compared using Fisher’s exact/Chi Square 
for dichotomous variables and t-test or Mann Whitney U test for continuous 
variables. Results are reported as statistically significant when p-values are <0.05.   
3.5 Results 
Data was available on all patients (n=77) in this prospective cohort.  Demographic 
data is recorded in (Table 3.1). Once daily AMP dosage regimes were: 10mg in n=69 
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(90%), 25mg in n=7 (9%) and 50mg in only n=1 (1%).  Total daily doses of GBP 
were 900mg in n=71 (92%), and 1.2-1.8g in n=6 (8%).  
3.5.1 Efficacy 
In 56% (43/77) there were reductions in VAS (5.3±3.6→2.8±2.7, P<0.0001) and ODI 
(42.8±31.1→30.7±25.2, P=0.008) (Table 3.1).  Improvement was less in those with 
AE: a trend existed for a lesser reduction in VAS (2.0±2.4 v 3.0±2.7, P=0.08) which, 
however, proved significant for ODI (8.1±11.4 v 16.7±18.2, P=0.01).  Total daily 
doses of GBP were 900mg in n=41, and 1.2-1.8g in n=2 in those with efficacy. Of 
those with efficacy, n=39 were taking AMP-10mg, n=4 were taking AMP-25mg, n=0 
were taking AMP-50mg. There was no significant difference between those with and 
without efficacy regarding the use of codeine-based analgesia ‘as required’ (22/43, 
51% v 20/34, 59%: P=0.57). 
3.5.2 Adverse Events 
Eighty-two AEs (23 types) were reported in 53% of patients (41/77) (Table 3.1). 
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Table 3.1 Patient characteristics – total population 
Description Value 
P – value  
(if applicable) 
Total population – n (%) 77 (100) - 
Age (years) - mean (range) 57 (21 – 89) - 
Sex, n (%)   
                  Male 
                  Female 
32(42) 
45(58) 
- 
 
Adverse Events – n (%) 
Efficacy - n (%) 
41(53) 
42(55) 
- 
Ceased Treatment <1wk – n (%) 26 (34) - 
VAS   
                 Start – mean (SD) 
                 Finish – mean (SD)  
5.31 (3.64) 
2.83 (2.72) 
<0.0001 
ODI   
                 Start – mean (SD) 
                 Finish – mean (SD)  
42.84 (31.12) 
30.74 (25.19) 
0.008 
 
As Table 3.2 lists, the most common AEs were amnesia (8/82, 9.8%), dizziness 
(8/82, 9.8%), confusion (7/82, 8.5%), and ataxia (6/82, 7.3%). Sixteen per cent 
(12/77) continued with GBP with no efficacy and no AE (Figure 3.1).  
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Figure 3.1 Venn diagram: efficacy versus side effects 
 
AEs were recorded in n=23/41 (56%) of females and n=18/41 (44%) males: a similar 
distribution pertained in those without AE (n=22/36 [61%] females, and n=14/36 
[39%] males) (P = 0.66).   Total daily doses of GBP were 900mg in n=37 (90%), and 
1.2-1.8g in n=4 (10%).  Of those with AE, n=39 (95%) were taking AMP-10mg, n=2 
(5%) were taking AMP-25mg and n=0 (%) AMP-50mg.  Of those without AE, n=30 
(83%) were taking AMP-10mg, n=5 (14%) were taking AMP-25mg and n=1 (3%) 
AMP-50mg.  There was no significant difference between those with and without AE 
regarding the use of codeine-based analgesia ‘as required’ (20/41, 49% v 20/36, 
56%: P=0.46). 
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Table 3.2 Adverse events experienced by population 
 
Description 
Frequency 
Proportion of  
population 
with side-
effect (%) 
Dizziness, Vertigo 11 27 
Drowsy, sedation, retardation 9 22 
Decrease Memory 8 20 
Confusion 7 17 
Dry Mouth, Heart Burn, 
Decreased taste 
6 15 
Ataxia 6 15 
Lethargy 5 12 
Bowel Disturbance 5 12 
Rash, Weight Gain 5 12 
Nausea, Vomiting, Headache 5 12 
Euphoria, Tingling 4 10 
Diplopia,  3 7 
Psychiatric Disturbance 3 7 
Auditory Hallucination 2 5 
Aggression 2 5 
Sleepwalking 1 2 
TOTAL 82 
3.5.3 Gabapentin Cessation 
Thirty-four per cent (26/77) discontinued GBP: all within 1 week (i.e. during titration).  
Of those who ceased GBP, n=24/26 (92%) had AE.  N=2 (8%) ceased because they 
had experienced no efficacy and because they had “expected” AE.  Of those who 
ceased GBP, n=5/26 (19%) had reported efficacy with AE. N=4/43 (9%) with efficacy 
ceased GBP because of AE.  Total daily doses of GBP were 900mg in n=24, and 
1.2-1.8g in n=2.  Of those who ceased GBP, n=1 was taking AMP-25mg, and n=1 
was taking AMP-50mg.   
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3.6 Discussion 
Our study results showed super-added GBP demonstrated further efficacy in 56% 
of patients: however, AEs were frequent (53%) and diverse (n=23); and 34% 
abruptly discarded GBP. The first prospectively randomised placebo-controlled 
study reported using GBP used unconventional outcome parameters (e.g. a Likert-
type scale was used to assess pain instead of the VAS) and specifically did not use 
the ODI (the ‘Gold standard’ to assess disability with low back conditions) (5).  In 
addition, the proportion reporting efficacy was not established since patients who 
did not tolerate even basal doses of the drug were withdrawn from the study. 
Blinding between GBP and placebo also remained uncertain, thus questioning the 
integrity of allocation concealment given that GBP must be introduced incrementally. 
Additionally, GBP requires an adequate trial of more than two months as per 
National Formularies, which would have been difficult to complete where high doses 
are required (7).  Finally, as aforementioned, AEs were recorded in only 8% (i.e. a 
much lower proportion than that recorded using GBP in other NP states) despite 
doses of up to 3600mg GBP having been administered (5, 9).  A second study in the 
literature examining GBP was a prospective open-label non-comparative study that 
did use the VAS and ODI: however, the study did not mention AE at all (6).   
Prospective cohort studies, such as ours, maintain representation because all 
patients were necessarily recruited.  In our study, all patients were taking a pre-
existent regime which had included AMP, as enforced by the prescribing authorities 
(Queensland Health Medicines Advisory Committee, QHMAC, and the 
Pharmaceutical Benefit Advisory Committee, PBAC). At the time of the study, 
subsidised GBP was not available for first-line treatment in CS.  Such a regime 
containing AMP had already proven partially effective, as reflected in moderate 
baseline scores for both VAS (5.3±3.6) and ODI (42.8±31.1).  Furthermore, no 
patient studied had reported significant AE on their pre-existent regime. Because 
patients were already taking AMP, and because those who had previously tried (and 
failed) AMP were disinclined to take GBP, it was not possible to obtain a control arm 
in our study in which either AMP or GBP could be prospectively prescribed alone.  
Furthermore, it was considered inequitable to ask patients to cease a pre-existent 
regime which had already proven partially beneficial solely to ensure a statistically 
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sound study. Indeed, this would have been against NICE-UK guidelines, where 
“overlap” with first-line agents and pre-existent regimes is encouraged precisely to 
avoid decreased pain-control.   
3.6.1 Efficacy 
Our results are compatible with previous studies where only GBP was used to treat 
other NP states.  For example, NICE-UK concludes that “patients taking GBP were 
significantly more likely to report at least 50% pain reduction and global 
improvement compared with patients taking placebo (moderate-to-high-quality 
evidence)”.  This is comparable to the 47% reduction in VAS seen in our study.  
However, the lower improvement in ODI (28%) observed in our study, by contrast, 
initially appeared divergent.  Nevertheless, as we subsequently discuss, both the 
VAS and (especially) the ODI were adversely affected by AE in our study.  Excluding 
those with AE, both scores were rendered compatible with the NICE-UK statement. 
This suggests that GBP when added to a pre-existent regime containing AMP in CS 
exhibits remarkably similar efficacy to that when GBP is prescribed alone in other 
NP states. 
3.6.2 Adverse Events  
An important aspect of our study was the complete documentation of AE.  National 
formularies (e.g. Australian Medicines Handbook (AMH), British national Formulary 
(BNF), European Pharmacopoeia) report no less than 16 types of AE associated 
with GBP in general use described as “common” (fatigue, sedation, dizziness, 
ataxia, tremor, diplopia, nystagmus, amblyopia, amnesia, abnormal thinking, 
hypertension, vasodilation, peripheral oedema, dry mouth, weight gain and rash), 
as well as a further 4 types described as “rare” (jaundice, movement disorders, 
myoclonus and allergic reactions) (8, 10, 11).  In marked contrast, regarding GBP use 
in non-CS NP states, NICE UK noted only 3 types of AE: i.e. dizziness, somnolence 
(moderate-quality evidence) and fatigue (low-quality evidence).  Indeed, regarding 
sedation and gait disturbance, NICE-UK reported “no significant differences” 
between patients taking GBP and patients taking placebo (very-low-quality 
evidence).    
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The 2 previous studies reported by Yildirim et al. (5, 6) also reported AEs that were 
both; lower frequency and diversity of type, compared to our study. However, it 
should be noted that that an undisclosed proportion of patients “who did not tolerate 
even basal doses of the drug” were immediately withdrawn from the study of Yildirim 
et al.: data from this subset was therefore unavailable (5). Moreover, Yildirim et al. 
later stated that a further n=7/23 (30%) had ceased GBP throughout the study 
period, compared to 34% in our study.  Given that the vast majority of patients who 
ceased GBP in our study (i.e. 92%) had suffered AE, it is very likely that the actual 
incidence of AE in the study of Yilidrim et al. had been grossly under-reported.  
3.6.3 Gabapentin Cessation 
An important aspect of our results (and others) was that of GBP cessation.  
Regarding GBP use in other NP states, NICE UK reported that patients taking GBP 
were “significantly more likely to withdraw from treatment because of adverse 
effects” compared with patients taking placebo (moderate-quality evidence).  As 
noted above, both studies by Yildrim et al. referred to a population of patients “who 
did not tolerate even basal doses of the drug”.  Thus, it is implicit in both studies that 
a definite proportion ceased GBP potentially at an early stage, such as during the 
initial GBP titration period.  Our results were more explicit.  Given the slow manner 
in which GBP is incrementally introduced, such findings suggest that many patients 
discard GBP before any efficacy could possibly have accrued.  Nevertheless, of 
those who ceased GBP, n=5/26 (19%) had reported efficacy, but with AE.  Overall, 
n=4/43 (9%) with efficacy had ceased GBP because of AE.  Indeed, of those who 
ceased GBP, n=24/26 (92%) reported AE.  Thus, the principal reason for abrupt 
GBP cessation related to either the development, or anticipation, of AE: not a lack 
of efficacy.  In this latter regard, n=2 (8%) ceased because they had experienced no 
efficacy, and because they had “expected” AE.   
3.6.4 Interaction of Adverse Events with Efficacy 
Probably the most interesting aspect of our study was that the occurrence of AE was 
associated with decreased GBP efficacy.  The statistically significant effect of AE on 
ODI may be associated with the fact that, as aforementioned, the overall mean ODI 
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improvement (28%) was somewhat lower than that expected from studies where 
GBP was used in other NP states using other measures. ODI improvement in those 
without AE was 39%: this proportion approaches that observed following spinal 
fusion for CS (49.5%) (12).  VAS improvement likewise improved from 47% in those 
with AE, to 62% in those without AE.   
It is not immediately clear from our study as to why AE were associated with 
decreased GBP efficacy.  Adverse psychological factors, associated with having 
experienced AE, could conceivably have impacted negatively upon pain perception.  
However, our study cannot provide any definite mechanism for the result observed.   
3.7 Conclusion 
This was the first prospective cohort study of GBP super-added to a pre-existent 
regime containing AMP for CS.  The study was therefore representative of clinical 
practice, and in accord with NICE-UK principles.  Super-added GBP demonstrated 
further efficacy in 56%: however, AE were frequent (53%) and diverse (n=23); and 
34% abruptly discarded GBP.  Such findings also endorse the study’s 
representation.  Although AE were associated with decreased efficacy, 37% 
nevertheless tolerated GBP despite AE. 
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Chapter 4 Pregabalin versus Gabapentin in the 
Treatment of Sciatica: A Study Protocol for a 
Randomised, Double-Blind and Cross-Over Trial 
(PAGPROS) 
‘Doubt is a pain too lonely to know that faith is his twin brother.” 
Khalil Gibran 
4.1 Background 
This protocol presents the design and rationale for a double-blind, double-dummy, 
randomised, cross-over trial comparing the efficacy of Pregabalin (PGB) to 
Gabapentin (GBP) in chronic sciatica (CS).  Due to the variability in regular dosage 
frequency between the medications (PGB = twice daily and GBP thrice daily), the 
design and implementation of this trial was complex. Thus, “PAGPROS” represents 
the first head-to-head study to determine the relative role of either PGB or GBP in 
the evidence-based medical management of CS.  However, in addition to efficacy, 
PAGPROS also determines the frequency and severity of adverse events (AEs) with 
PGB or GBP.  Thus, PAGPROS examines the ‘efficacy v AE trade-off’ with each 
drug. 
Chapter 4 of this thesis, entitled “Pregabalin versus Gabapentin in the Treatment of 
Sciatica: A Study Protocol for a Randomised, Double-Blind and Cross-Over Trial” is 
based on the manuscript published in the journal BMC Trials. The paper is inserted 
into this thesis with minor modifications. Only the formatting of section sub-
headings and numbering of tables and figures have been modified from the original 
publication to match the thesis format. The referencing of the chapter retains the 
original journal style. 
Robertson K, Marshman L, Hennessy M, Harriss L, Plummer D. (2017). 
Pregabalin versus Gabapentin in the Treatment of Sciatica: A Study Protocol 
for a Randomised, Double-Blind and Cross-Over Trial. BMC Trials: January 
19:21 https://doi.org/10.1186/s13063-017-2400-y 
 
 
48 
 
4.2 Abstract 
Background: There is currently an absence of high grade evidence regarding the 
treatment of CS.  Whilst GBP and PGB are both currently used to treat CS, equipoise 
exists regarding their individual use.  In particular, no head-to-head study of GBP 
and PGB in CS exists. Despite equipoise, most countries’ formulary regulation 
authorities typically favour one drug for subsidy over the other: this hinders 
interchange wherever the favoured drug is either ineffective or not tolerated. 
Primary Aim: To compare head-to-head the efficacy of PGB versus GBP for CS by 
outcomes on Visual Analogue Scale (VAS) and Oswestry Disability Index (ODI). 
Methods: Prospective, randomised, double-blind, double-dummy cross-over study. 
Included patients were over 18 years, and suffer unilateral CS with radiological 
confirmation of corresponding neural compression/irritation. Pregnant women, those 
with major organ disease, or creatinine clearance <60ml/min were excluded.  
Patients continued their current pain medication at study onset conditional upon 
dosage consistency during the prior 30 days.  Each drug was titrated up to target 
dose (GBP: 400-800mg tds, PGB: 150-300mg bd) and taken for 8 weeks.  The first 
drug was then ceased: however, cross-over occurred after a 1-week washout 
period. Drug efficacy was assessed by the visual analogue scale and Oswestry 
Disability Index. The Health Locus of Control (HLoC) Scale and AE 
frequency/severity determined psychological functioning. Assuming the hypothesis 
that one drug will display a superior effect, the sample size required is n=38 with 
80% power and 5% type 1 error rate. Results were analysed via intention- to-treat 
methodology.  
Discussion: This study establishes the efficacy of PGB compared with GBP in 
reducing pain for people with CS and leads to greater understanding of the treatment 
options available. 
Trial Registration Number: Australian and New Zealand Clinical Trial Register: 
12613000559718 (registered 17.05.13) 
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4.3 Introduction 
Sciatica or sciatic neuralgia, a common form of lumbosacral radiculopathy, is 
characterised by low back pain which radiates to the leg and which may be 
accompanied by sensory loss, motor weakness and/or reflex abnormalities. Sciatica 
is a symptom defined as well-localised leg pain, with a sharp, shooting or burning 
quality that approximates to the dermatomal distribution of the sciatic nerve down 
the posterior lateral aspect of the leg (1).  It is often associated with numbness or 
paraesthesia in the same distribution but typically extends beyond the limits of 
perceived pain in either a dermatomal or sclerotomal anatomical fashion (2, 3). The 
term “sciatica” is used by clinicians in different ways; some refer to any leg pain 
referred from the back as sciatica; others prefer to restrict the term to pain originating 
from the lumbar nerve root. Others believe sciatica is a form of 'neuropathic' pain 
(NP) caused by compression or irritation of the roots or nerves that comprise the 
sciatic nerve (1, 4). CS is sciatica which has been present for more than 3 months 
despite active conservative management, including physical therapy. CS may 
complicate previous chronic low back pain: however, it may also present purely as 
an isolated phenomenon (1, 4).  
The annual prevalence of CS varies widely (1.6-43%) with male predominance (4). 
CS accounts for 5% of low back pain presenting to primary care and 30% of sufferers 
have persistent pain for greater than 12 months (4). Of these 30% presenting to 
primary care, 20% are already out of work and 5-15% require surgery. Over half of 
CS sufferers will have pain 4 years post diagnosis with the socio-economic cost per 
country per year is estimated at $128million in hospital care, $730million for 
absenteeism and $708million for disablement (5). 
Anti-depressants such as tri-cyclic antidepressants (TCAs: e.g. Amitriptyline AMP) 
are widely used to treat NP including CS, first line after failure of simple analgesics.  
Based on ‘moderate-quality’ evidence, The National Institute for Clinical Excellence 
–United Kingdom (NICE-UK) reported TCA efficacy over placebo for NP (6): 
however, based on ‘high-quality’ evidence, TCAs were also significantly more likely 
to produce AE than placebo.  Extrapolating NICE-UK guidelines, prescribing 
authorities (e.g. Australian Therapeutic guidelines, ATG) often insist on trialling 
TCAs first for NP, prior to introducing second-line agents.  Limited information, 
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however, is available regarding TCA use in CS.  In one rare cross-over study, 
Nortriptyline – alone, or combined with Morphine – had no significant benefit over 
placebo (6).   
Anticonvulsant anti-neuropathic agents such as GBP and PGB are also widely used 
to treat NP, including CS.  Based on ‘moderate-to-high-quality’ evidence, NICE UK 
noted efficacy of these agents over placebo for NP (6). Australian prescribing 
authorities (e.g. ATG) recommend anti-neuropathic agents as second-line agents 
for NP, even though NICE-UK did not actually favour TCAs over anti-neuropathic as 
first-line agents (or vice versa).  However, when introducing second-line agents, 
NICE-UK states that “overlap” with pre-existent regimes should be considered to 
avoid decreased pain-control (6).  A recent literature review provides individual 
efficacy of PGB and GBP over placebo for CS, however when compared head to 
head no firm conclusions can be made (7).  
In summary, CS, like most NP states, often proves resistant to simple analgesic 
regimes (including paracetamol, non-steroidal anti-inflammatory agents, or opioids) 
and recommended first line TCA’s (1, 4). Instead, the drugs most commonly used 
currently in both CS and NP are GBP or PGB (1, 4). PGB and GBP are both 
analogues of gamma-aminobutyric acid (GABA), a substance known to modulate 
calcium-channel subunits.  Both GBP and PGB may therefore possibly act by 
decreasing neurotransmitter release associated with central sensitisation in both CS 
and NP. 
As with NP, there is currently an absence of high-grade evidence regarding the 
medical treatment of CS (1, 6).  No adequately powered direct ‘head-to-head’ trials 
comparing either PGB or GBP with other drugs are extant (1, 6).  Indirect 
comparisons, using placebo as the common comparator, have been published: 
however, each have presented differing patient populations, differing primary 
outcomes, as well as differing pain measurement scales (6). A recent review 
concluded, albeit based on weak evidence, that efficacy and AE with GBP and PGB 
were probably similar (7).  
Notwithstanding, citing minor titration but definite cost advantages, NICE-UK 
nevertheless favoured PGB over GBP (6).  However, costs for either PGB or GBP 
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vary widely globally.  Moreover, costs vary unpredictably (i.e. PGB more expensive 
than GBP, or vice versa) on a global basis (7).  Despite this, formulary regulation 
authorities in most countries have, like NICE-UK, favoured one drug over the other.  
Furthermore, and somewhat paradoxically, formulary regulation authorities in most 
countries have typically favoured the more expensive drug: whether GBP or PGB 
(7). For example, GBP is currently available on the PBS in Australia and some 
hospitals in the UK only for epilepsy: it is not listed for NP. PGB, by contrast, is 
subsidised on the Australian Pharmaceutical Benefits Scheme (PBS) for NP. The 
Food and Drug Administration (FDA) in the USA, along with Health Canada, have 
adopted similar reimbursement criteria to that of the Australian PBS: 
notwithstanding, both GBP and PGB can be accessed in the USA and Canada via 
special access schemes (if patients satisfy stringent criteria for NP).  In marked 
contrast, GBP is listed for use in both partial seizures and NP throughout Europe.  
The rulings of formulary regulators have therefore been inconsistent, and dependent 
upon the individual body.  Such action hinders interchange wherever the favoured 
drug is either ineffective or not tolerated (7).  Given that no evidence supports 
unhindered PGB-GBP interchange, and that no study has directly challenged GBP 
and PGB head-to-head, neither GBP nor PGB should probably be favoured given 
current evidence (7).   
Prospective ‘head-to-head’ studies are therefore urgently required to provide robust 
evidence-base for GBP or PGB use in CS (4). Both medications have previously 
displayed efficacy when compared to placebo (1, 8, 9). We therefore present a protocol 
for the first study to assess GBP and PGB directly head-to-head in CS. 
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4.4 Objectives 
4.4.1 Primary Objective and Outcome 
To demonstrate if either GBP or PGB demonstrates superiority over the other in 
terms of efficacy for the treatment of patients diagnosed with CS.  
The co-primary outcome is leg pain intensity using the Visual Analogue Scale (VAS) 
measured at baseline and at weeks 4, 8, 10, 14 and 18. The participants were asked 
to rate their average leg pain over the last 24hours out of 10, with zero representing 
‘no leg pain’, and 10 representing the ‘worst pain imaginable (10). 
The co-primary outcome is the Oswestry Disability Index (ODI) Questionnaire (10), 
measured at baseline and at weeks 4, 8, 10, 14 and 18, to assess disability. The 
Health Locus of Control (HLoC) survey was used at baseline and at weeks 4, 8, 10, 
14 and 18 to assess participants decision making processes as we have identified 
compliance with these medications being low (10). 
4.4.2 Secondary Objective and Outcome 
To demonstrate if one drug (i.e. either GBP or PGB) demonstrates superiority over 
the other in terms of the frequency and severity AEs in the treatment of CS. 
The key secondary outcome was the record of frequency and severity of AEs. 
Details of AE will be collected at weeks 4, 8, 10, 14 and 18.  The most common AE 
of PGB are dizziness and somnolence (11). The most common AEs of these 
medications are dizziness (27%), drowsiness (22%) and decreased memory (20%) 
(10). 
4.5 Methods 
PGB and GBP prospective clinical trial for the treatment of sciatica (PAGPROS) is 
a double-blind, randomised, double-dummy, cross-over trial comparing PGB to GBP 
in the treatment of CS (Figure 4.1). 
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Figure 4.1 CONSORT Flow Diagram for PAGPROS 
Assessed for eligibility 
Excluded 
Not meeting inclusion criteria 
 Declined to participate  
 Other reasons (n= ) 
Analysed 
 Excluded from analysis 
 Lost to follow-up  
 Discontinued intervention 
Allocated to intervention sequence AB (n=19) 
 Received allocated intervention (Gabapentin) 
- 8-week treatment period 
 Lost to follow-up 
 Discontinued intervention  
Allocated to intervention sequence BA (n=19) 
 Received allocated intervention (Pregabalin) 
- 8-week treatment period 
Analysed 
 Excluded from analysis 
 
 Informed consent obtained and baseline data collected 
 
  
Allocated to intervention sequence AB (n=19) 
 Received allocated intervention (Pregabalin) 
- 8-week treatment period 
 
Allocated to intervention sequence BA (n=19) 
 Received allocated intervention (Gabapentin) 
- 8-week treatment period 
 
Randomised (n=38) 
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Ethics approval was obtained from the local HREC, and the study has been 
registered (Australian and New Zealand Clinical Trial Registry (ANZCTR) 
12613000559718).  The study protocol follows the SPIRIT statement (12) and a 
CONSORT diagram are provided (Figure 4.1). 
4.5.1 Participants and Recruitment 
Participants were recruited from attendance at a specialist neurosurgery clinic in a 
large tertiary hospital located in Townsville Australia, who had unilateral CS. The 
study specialists comprising consultant neurosurgeons performed a medical 
evaluation to gain relevant medical and medication history, and screened the patient 
against the eligibility criteria. This initial intervention included baseline scores for 
VAS, ODI and HLoC. The patient was then directed to the trial pharmacist who 
remained independent of the treating team, for consenting and signature of the 
informed consent document.  
Patients were deemed eligible if they meet all the following criteria:   
• Pain radiating into one leg only to, at, or below knee level 
• Magnetic Resonance Imaging (MRI)/Computed Tomography (CT) 
confirmed sciatica caused by a degenerative condition (e.g. degenerative 
disc disease, bone spur growth, degenerative scoliosis)  
• Naïve to PGB and GBP usage  
• Age 18 years or older 
• Sufficient understanding of the English language or interpretation 
assistance available to complete the study treatment and assessments. 
Concomitant medication including analgesics and Central Nervous System (CNS) 
depressants (Paracetamol, NSAIDS, and Opioids) could be continued as long as 
the medication dose has been stable 30 days prior to the start of the study.  
Patients were excluded if they meet any of the following criteria:  
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• Pregnant or breastfeeding women; or females planning conception during 
the study period 
• Patient history or laboratory results that suggest the presence of inherited 
neuropathy, or neuropathy attributable to other causes (hypothyroidism, 
B12 deficiency, connective tissue disease, amyloidosis, toxic exposure) 
• Major organ system disease; diabetic cardiovascular autonomic neuropathy 
with abnormality in sympathovagal balance; baseline postural hypotension 
of more than 20mm Hg 
• Specific contraindications to PGB or GBP (allergy to, or significant renal 
impairment). PGB and GBP are both predominantly renally excreted, so 
patients with an estimated creatinine clearance of<60 ml/minute will be 
excluded 
• Other neurologic medications such as serotonin reuptake inhibitors 
(Paroxetine, Fluoxetine), Dual (serotonin and noradrenaline) reuptake 
inhibitors (Venlafaxine), benzodiazepines, anticonvulsant medications 
(Valproic acid, Carbamazepine), antipsychotic medications (Clozapine, 
Olanzapine, Risperidone) or bipolar disorder medications (Lithium) 
• People with a diagnosis of cancer; dementia, severe mental illness or other 
condition which will significantly reduce the ability to consent and/or fully 
undertake the program. 
• Diabetic and /or HIV-related neuropathies. 
If a patient is eligible, the unblinded independent trial pharmacist gained informed 
consent and notified the research team. The participant was then randomised and 
the pharmacist dispensed and counselled on the study medications, and arranged 
visit appointments with reminders. At this point, baseline data was confirmed by the 
pharmacist as collected at the first visit, or subsequently via telephone, before the 
participant commenced the study medication. Following baseline data collection, the 
researcher informed the participant to break the seal on the medication pack and 
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commence the study medicine as per the dosage instructions.  At this point the 
participant was considered to have been included into the study. 
To ensure consistency, the study researchers ensured that the protocol was 
followed, and that Good Clinical Practice was monitored. General practitioners were 
able to refer community patients into the trial, via a trial specialist hotline contact 
number, whereby the patient is screened by a study specialist to ensure consistency 
of enrolments.  
4.5.2 Randomisation and Blinding 
The trial pharmacist (un-blinded) generated a randomisation code using a computer-
derived permuted block with varying block size sequence. Manufacturing and 
preparation of the medication capsules were performed by an external Good 
Manufacturing Practice (GMP) accredited facility. The unblinded pharmacist was 
involved in the preparation of the medication kits as per the randomisation schedule. 
The sequence was a 2x2 sequential design where participants received PGB first, 
then subsequently GBP (or vice versa) in a double-blinded fashion. Due to the 
variability in regular dosage frequency between the medications (PGB = twice daily, 
GBP = thrice daily) study medication packs contained 3 bottles each correlating to 
the dosage times of morning, lunch, and night, to maintain blinding. Medication 
packs pertaining to the PGB arm have a placebo incorporated as the lunch time 
dose with all medications being indistinguishable. The randomisation schedule 
remained concealed from other researchers. Placebo capsules had an identical 
appearance to the active capsules.  The randomisation process ensured concealed 
allocation and blinding of the specialist, the participant and the outcome assessor.  
4.5.3 Study Treatment 
Participants were randomised to commence treatment on either PGB or GBP. 
Because of the cross-over methodology, participants had the opportunity to 
experience both PGB and GBP and we predicted little or no carry-over effects 
(medium or long term) after the washout period. We believe the incorporation of 
standalone placebo arm is unethical in trials where participants with moderate to 
severe pain are recruited.  
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The starting dose of PGB was 150mg once daily for the first week. This was then 
titrated to the participant’s optimal dose, up to a maximum of 300mg twice daily, 
depending on their progress and tolerability at each dose level. The starting dose 
for GBP was 400mg once daily for the first week. This was then titrated to the 
participant’s optimal dose, up to a maximum of 800 mg thrice daily, depending on 
their progress  and tolerance  at each dose level. These doses were based on 
national recommendation from the Australian Medicines Handbook (11). In the 
standard study dosing regimen (Table 4.1), a 4-week titration period, after which the 
maximum tolerated dose for each participant will be maintained for 4 weeks before 
the first study medication is ceased preparing for washout. The washout period 
between treatment phases lasted 1 week which was sufficient for these medications 
as they possess a short half-life (5-7 hours). The dosage of either PGB or GBP could 
be amended at any stage in PAGPROS based upon efficacy and/or AE by 
communication between the study specialist and the study pharmacist. The 
maximum treatment period was 8 weeks (13).  
Table 4.1 PAGPROS medication titration schedule 
Week Pregabalin Total Daily Dose 
1 1 x 150mg capsule in the morning 150mg/day 
2 1 x 150mg capsule three times a day (middle 
dose is placebo) 
300mg /day 
3 -8 2 x 150mg capsules three times per day (middle 
dose is placebo) 
600mg/day 
Week Gabapentin Total Daily Dose 
1 1 x 400mg capsule in the morning 400mg/day 
2 1 x 400mg capsule three times per day 1200mg/day 
3-8 2 x 400mg capsules three times per day 2400mg/day 
 
The titration and dosage regime was based on recommendations from clinical 
practice and medication guidelines such as the Australian Medicines Handbook and 
product Prescribers Information. Both medications have the potential for adverse 
neurological side effects and hence a slow ascent in dose contributed to mitigating 
this risk for participants and increasing compliance on the trial. Simultaneously prior 
to washout, the dosage was gradually reduced instead of an abrupt halt further 
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decreasing the likelihood of medication misadventures for the participants (and 
increasing compliance). 
In addition to PGB or GBP, participants could continue concomitant medications 
(including analgesics) if the dosage has been stable for 30 days prior to commencing 
the study period. These concomitant medications were closely monitored and 
recorded as part of the case report form. Medicines for NP include antidepressants, 
selective serotonin and noradrenaline re-uptake inhibitors, topical lignocaine and 
other anticonvulsant medications (14). Note that this practice is entirely consistent 
with NICE-UK guidelines which states that, when super-adding second-line agents 
for analgesic control (such as GBP and PGB), “overlap with first-line agents is 
encouraged to avoid decreased pain-control”.  To our knowledge, only one 
prospective cohort study has reflected this practice with GBP in CS (14). However, 
participants should not take concomitant medication that could result in an adverse 
interaction with PGB or GBP, including medicines that might increase the risk of 
excessive sedation (for example, benzodiazepines) (11). No other pain interventions 
were permitted throughout the period of study: if considered necessary, then such 
patients were withdrawn from PAGPROS. 
Participating in PAGPROS was completely voluntary and participants could stop 
taking part at any time without explanation or prejudice. Ceasing to participate in 
PAGPROS may be considered, for example, wherever participants wish to explore 
the possibility of other treatments, including other medications or interventions (see 
above).  In some cases, participants may find that the starting dose of either PGB 
or GBP, whilst efficacious, produces unwanted AE (10).  In such cases, a lower dose 
may be required: at least for a period of time.  Because this cannot be 
accommodated within the current PAGPROS protocol, such patients were removed 
from the study and data analysed as per intention-to-treat (ITT) principles: however, 
they could still form part of a prospective cohort for parallel study.    
4.5.4 Data Collection 
Data collection was conducted by the study researchers via telephone, email or 
online at baseline (before medication commencement) and at weeks 4, 8, 10, 14 
and 18. Week 10 data collection acted as the cross-over secondary baseline for 
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analysis purposes.  Data was entered into Case Report Forms by dedicated trained 
staff. Each participant received up to seven face-to-face or telephone consultations 
with the trial pharmacist to commence treatment, monitor progress and adjust the 
dose of the study medication over the 8-week treatment periods. These visits 
incorporated a medical evaluation and collection of primary and secondary 
outcomes. Participants received usual neurosurgical care independent of, and 
parallel to, PAGPROS. 
The use of prior and continued analgesic medicines were collected at baseline. 
Adherence to   study   medication   was documented through a self-reported daily 
medication diary and by counting the returned medicine, compared to the prescribed 
regimen as recorded by the trial pharmacist.  Participants were asked to return used 
and unused study medications at each visit. 
4.5.5 Data Integrity and Analysis 
The integrity of trial data was monitored by regularly scrutinising data files for 
omissions and errors. Double data entry was performed of the primary and key 
secondary outcomes. The source of any inconsistencies explored and resolved. 
Electronic data stored on a secure server and paper copies located in a locked 
cabinet.  Data was only accessible by researchers, and participant confidentiality 
maintained through secure password protected data storage, during and post-
PAGPROS. 
Data was de-identified prior to statistical analysis and performed on an intention-to-
treat basis. Normality of data distribution assessed, and appropriate parametric 
(Students t-test or ANOVA) or non-parametric tests (Wilcoxon signed rank, Wilcoxon 
rank sum) for between-groups differences performed. Statistical significance 
assessed at P<0.05. Subgroup analysis may be implicated and considered as 
PAGPROS develops. Time to event analysis undertaken using Kaplan Meier 
estimates on the week 8 and week 18 VAS scores. Missing data handled by a single 
imputation method whereby the last observation will be carried forward and used as 
a surrogate for the missing value. This method is the favoured approach for 
replacing missing data as it is conservative, yields an appropriate estimate of 
variation in outcome and is unlikely to bias towards the alternative hypothesis (15). 
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An alternative approach to missing data may be use of a longitudinal mixed-effects 
model incorporated into the analyses.  
4.5.6 Sample Size 
We hypothesize that over an 8-week treatment period GBP will reduce pain on the 
VAS scale by an average of 4.5 points from (7.5 to 3.0) as per historical literature 
(16). We predict PGB to show at least the same benefit. We hypothesize that PGB 
will display superiority over GBP by at least 20% better relative reduction in VAS 
score with a resultant reduction of 5.4 (7.5 to 2.1) points from baseline. This 20% 
relative reduction is based on the average reduction of pain symptoms compared to 
placebo for indirect comparisons (1, 16). Relative reduction will be used as it is often 
more impressive, and also to allow for the instance of a lower than expected event 
rate which would lower the absolute risk reduction.   
If the true difference in mean both arms of the study means is 0.9, with a standard 
deviation of 1.2, to detect this 20% relative decrease in pain between GBP and PGB 
we will need to study 30 patients (15 per treatment arm) in order to reject the null 
hypothesis with 80% power. The type 1 error probability associated with this test of 
the null is 0.05. Assuming a 20% drop-out rate the total sample size will be 38 
patients (19 per treatment arm). We have chosen this large effect size and 
conservative standard deviation based on anecdotal and specialists experience with 
this cohort of patients. The benefits of the cross-over methodology are evident with 
the small sample size required, due to each participant acting as their own controls. 
If this was a conventional parallel study design, sample size would be approximating 
to 100 participants.   We conservatively estimate that if two people can be recruited 
per week the study duration will be approximately 1.5 years. 
4.5.7 Adverse Events and Monitoring 
Potential risks of both PGB and GBP have been well studied due to its use in 
neuropathic conditions. These risks have been minimised by our exclusion criteria. 
Any AEs were monitored weekly during follow-up phone-calls and examinations. 
Close monitoring of other neurological pain medications occurred with patient 
diaries. AEs were quantified in a latest meta-analysis and given the rare AEs of both 
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medications and its likely effectiveness; the potential benefits outweigh the risks in 
this study (17). 
During the recruitment period a monitoring visit was applicable. The responsible 
monitor was a specialist neurosurgeon not involved in the conduct of the trial and is 
Chair of the Hospital patient safety committee. The purpose of monitoring is to: 
• Ensure that the study is conducted according to the protocol and applicable 
guidelines and regulations 
• Verify source data against data on the CRF and database 
• Check the security of stored data 
• Confirm that the consent process, approved by the HREC have been 
followed and view a random sample of original signed consent forms 
• Review all serious adverse events. 
Interim data monitoring took place in-house for review of safety and AEs. The trial 
could be stopped if more harm to patients is shown. The Pocock boundary could be 
used as the stopping rule, where after each set of 2n patient responses to a total of 
“K” looks at the data. This is a group sequential approach where the critical boundary 
(p<0.018) will be set at each look. 
An AE is the appearance or worsening of any undesirable sign, symptom, or medical 
condition occurring after starting the study even if the event is not considered to be 
related to the investigational drug. Any serious adverse event (defined as an event 
that is life  threatening,  results  in  death,  hospitalisation, or significant  disability) 
were reported  immediately  to the relevant authorities (study monitor, ethics 
committee, data safety monitoring board). If a potential relationship was suspected 
between the study drug and serious adverse event, then un-blinding to treatment 
allocation was indicated and the participant withdrawn from PAGPROS.   
Abnormal laboratory values or test results constitute AEs only if they induce clinical 
signs or symptoms, are considered clinically significant or require therapy. The 
occurrence of adverse events was sought by non-directive questioning of the patient 
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at each visit during the study. AEs were also detected when they are volunteered by 
the patient during or between visits or through physical examination, laboratory test 
or other assessments. 
All AEs were recorded with: 
• Severity grade – mild, moderate, severe. 
• Relationship to investigational drug – suspected/not suspected 
• Duration 
• Continuation to a serious adverse event (SAE). 
All AEs are treated appropriately. The action taken to treat the AE was recorded. A 
serious adverse event (SAE) is defined as: 
• Fatal or life-threatening 
• Results in persistent or significant disability/incapacity 
• Constitutes a congenital anomaly/birth defect 
• Requires inpatient hospitalisation or prolongation of existing hospitalisation. 
To ensure patient safety, every SAE regardless of suspected causality, occurring 
after the patient has provided informed consent and until 7 days after the patient has 
stopped study participation, was notified by expedited reporting to the Townsville 
Hospital and Health Service Human Research Ethics Committee. 
4.5.8 Modification of the Protocol 
Any modifications to the protocol that may impact on the design and conduct of the 
study required a formal protocol amendment.  Such amendment was agreed upon 
by the study investigators and approved by the local ethics committee prior to 
implementation.  Once approved, the changes communicated to the relevant 
parties. 
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4.6 Discussion 
The PAGPROS protocol presents the design and rationale for a double-blind, 
double-dummy, randomised, cross-over trial comparing the efficacy of PGB to GBP 
in CS.  Due to the variability in regular dosage frequency between the medications 
(PGB = twice daily, GBP = thrice daily) study medication packs contained 3 bottles 
each correlating to the dosage times of morning, lunch, and night, so as to maintain 
blinding. Medication packs pertaining to the PGB arm had placebo incorporated as 
the lunch time dose with all medications being indistinguishable.   
Thus, PAGPROS represents the first head-to-head study to determine the relative 
role of either PGB or GBP in the evidence-based medical management of CS.  
However, in addition to efficacy, PAGPROS also determined the frequency and 
severity of AE with PGB or GBP.  Thus, PAGPROS determined the ‘efficacy v AE 
trade-off’ with each drug, and whether differences in compliance rates result in 
consequence.  For example, in a prior study with GBP in CS, 31% patients ceased 
GBP within one week of treatment (10).  Moreover, efficacy was significantly less in 
those who suffered AE in that study (10). 
PAGPROS employs the HLoC questionnaire to assess psychological functioning 
with PGB or GBP in CS.  In particular, PAGPROS explores the prognosis of each 
drug relating to questionnaire outcomes relating to patient’s insight into their 
psychological dysfunction.  Thus, PAGPROS determines deficits and provides not 
actually reported as AE by the patients themselves.  This proves an important aspect 
of the study.  For example, a prior prospective cohort study with GBP in CS revealed 
that, of 23 different AE types amongst 53% patients, more than half could have 
adversely affected the ability to drive a motor vehicle safely, or even to maintain 
employment (10).   
Finally, the double-blind cross-over design of PAGPROS provides guidance 
regarding the implications of any potential need to substitute one drug for the other.  
For example, PAGPROS determines whether AE experienced with one drug is also 
observed with the other: i.e. in the same patient, in close temporal succession after 
cross-over.  This proves especially important should PAGPROS demonstrate a 
between-groups null effect regarding efficacy.  However, PAGPROS shows 
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significant efficacy to one drug, yet no efficacy to the other.  Despite a lack of 
evidence-base, many formulary regulation authorities world-wide typically favour 
one drug for subsidy over the other (4). This hinders interchange wherever the 
favoured drug is either ineffective or not tolerated (4).  The nature of PAGPROS’ 
design directly assesses the utility of cross-over between PGB and GBP, and 
therefore enables formulary regulation authorities to make more informed 
therapeutic decisions than at present. 
Recruitment commenced in early 2016, with data collection completed by late 2018. 
The allocation concealment and double-blind design minimises bias, while data 
collection processes ensure data quality and integrity. The trial team has extensive 
experience in the design, conduct and reporting of clinical trials. Results of the study 
are disseminated via publications and presentations.  
4.7 Potential Weaknesses of PAGPROS 
4.7.1 Treatment Duration  
PAGPROS permits a 4-week titration period, after which the maximum tolerated 
dose for each participant will then be maintained for 4 weeks.  The duration of 
individual drug study is, therefore, 8 weeks.  In some rare cases, this might be 
considered insufficient time to test efficacy at optimum dose (10).  Furthermore, since, 
anecdotally, some patients develop tolerance to AE incurred with either PGB or 
GBP, the study period may also be too short to detect AE tolerance.  
4.7.2 Dosages 
Given the restricted doses and study time available in PAGPROS, it is not possible 
to introduce either drug in ‘low and slow’ fashion (4).  Since the latter potentially off-
sets the development of AE, PAGPROS may therefore potentially over-estimate AE 
with either drug.  However, at least with GBP, there exists some control, in that a 
prospective cohort study found AE in 53% patients with CS (10).   
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4.7.3 Maintenance of Background Therapies Including Prior Analgesia  
This may affect both efficacy and AE development: potentially increasing both.  
However, note that this practice is entirely consistent with NICE-UK guidelines (6, 10); 
and, indeed, standard clinical practice.  NICE-UK guidelines state that, when super-
adding second-line analgesic agents (such as GBP and PGB), “overlap with first-
line agents is encouraged to avoid decreased pain-control” (6).  To our knowledge, 
only one prospective cohort study has reflected this practice, using GBP in CS (10). 
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Chapter 5 Effect of Gabapentin versus Pregabalin on 
Pain Intensity in Adults for Treatment of Chronic 
Sciatica: A Randomised Clinical Trial 
‘It is during our darkest moments that we must focus to see the light.’ 
Aristotle 
5.1 Background 
We performed a stringent single-site study using robust definitions of chronic 
sciatica (CS). It is important to note that at this stage in the patient's management, 
either Pregabalin (PGB) or Gabapentin (GBP) would be the next treatment routinely 
offered: either as an alternative to surgery (with its greater attendant risks), or as a 
penultimate step before committing to surgery. That is, patients will be offered either 
drug at this stage in their management irrespective of whether they actually 
participate in the study. It is also important to note that a position of equipoise 
genuinely exists regarding which drug (i.e. PGB or GBP) to prescribe in this 
situation. We believe that we had a responsibility to establish the best treatment 
option for the benefit of all CS patients.   
Chapter 5 of this thesis, entitled “Effect of Gabapentin versus Pregabalin on Pain 
Intensity in Adults for Treatment of Chronic Sciatica: A Randomised Clinical Trial” is 
based on the manuscript published in JAMA Neurology. The paper is inserted into 
this thesis with minor modifications. Only the formatting of section sub-headings 
and numbering of tables and figures have been modified from the original 
publication to match the thesis format. The referencing format of this chapter retains 
the original journal style. 
Robertson K, Marshman L, Plummer D, Downs E. (2018). Effect of 
Gabapentin versus Pregabalin on Pain Intensity in Adults for Treatment of 
Chronic Sciatica: A Randomised Clinical Trial. JAMA Neuro. Published online 
October 15, 2018. http://doi:10.1001/jamaneurol.2018.3077 
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5.2 Abstract 
Importance: Optimal pharmacological treatment for CS is currently unclear. While 
GBP and PGB are both currently used to treat CS, equipoise exists. Never-the-less, 
pharmaceutical regulation authorities typically subsidise one drug over the other. 
This hinders interchange wherever the favoured drug is either ineffective or ill-
tolerated. 
Objective:  To assess ‘head-to-head’ GBP vs PGB for the treatment of CS.  
Design: A pre-planned interim-analysis of a randomised, double-blind, double-
dummy cross-over trial of PGB versus GBP in CS, at half the estimated final sample 
size, was performed.  
Setting: Single-centre, tertiary referral Australian public hospital. 
Participants:  Patients attending a specialist neurosurgery clinic in a large tertiary 
hospital, with unilateral CS, were considered for trial recruitment. CS was defined 
as pain lasting for at least 3 months radiating into one leg only to, at, or below the 
knee level. Imaging (MRI, with or without CT) corroborating a root-level lesion 
concordant with symptoms and/or signs was determined by the trial clinician. 
Inclusion criteria also included patients being naïve to both GBP and PGB, patients 
18 years of age or older. 
Interventions: Randomly assigned participants received GBP (400-800mg thrice-
daily) then PGB (150-300mg twice-daily), or vice versa, each taken for 8 weeks. 
Cross-over followed a 1-week washout.  
Main Outcome(s) and Measure(s): The primary outcome was pain intensity (10-
point Visual Analogue Scale, VAS) at baseline and 8 weeks. Secondary outcomes 
included: disability (Oswestry Disability Index ODI), and severity/frequency of 
adverse events (AE). 
Results: N=20 underwent randomisation.  This equated to n=40 drug and patient 
episodes. N=2 were excluded. Both GBP (P<0.0001) and PGB (P=0.002) displayed 
significant VAS-reduction, and ODI-reduction (P<0.001 for both). ‘Head-to-head’, 
GBP showed superior VAS-reduction (GBP:1.72±1.17 v PGB:0.94±1.09, P=0.035) 
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irrespective of sequence order: however, ODI-reduction was unchanged.  PGB-AE 
were more frequent (PGB=31 v GBP=7, P=0.002): especially when PGB was taken 
first (P<0.001). ‘Central Nervous system’ PGB-AE were significantly more severe 
(P<0.05). AE significantly reduced GBP ODI-efficacy.   
Conclusion and Relevance: PGB and GBP were both significantly efficacious. 
However, GBP was superior, with fewer/less severe AE.  GBP should be 
commenced before PGB to permit optimal cross-over wherever PGB may ultimately 
be warranted.  
Trial Registration: Australian and New Zealand Clinical Trial Register: 
12613000559718: http://www.anzctr.org.au/ 
5.3 Introduction 
CS, like other neuropathic pain (NP) states, is often resistant to simple treatment 
regimens (1, 2). CS is sciatica lasting more than 3 months (3). NP states are typically 
managed by super-adding anti-convulsant drugs onto simple drug regimens.  The 
drugs most commonly used are GBP or PGB. CS, has therefore been increasingly 
treated with super-added GBP or PGB (1, 2, 4). PGB and GBP are both analogues of 
gamma-aminobutyric acid (GABA), a substance known to modulate calcium-
channel subunits.  Both GBP and PGB may therefore possibly act by decreasing 
neurotransmitter release associated with central sensitisation in both CS and NP.   
Optimal pharmacological treatment for CS is unclear. In particular, the precise role 
of the two principal drugs, PGB or GBP, in treating CS has been surprisingly under-
explored (5).  
Thus, while GBP and PGB are both currently used to treat CS, a position of 
equipoise appears to exist regarding which to choose (6). Notwithstanding, 
pharmaceutical regulation authorities across different countries typically subsidise 
one drug over the other. This hinders interchange wherever the favoured drug is 
either ineffective or not tolerated.  Paradoxically, in many countries, the drug 
favoured for subsidy has actually been the more expensive: regardless whether 
PGB or GBP was chosen (6). 
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A prospective randomised placebo controlled trial recently demonstrated a null 
effect for PGB in treating ‘sciatica’.  However, this study included patients recruited 
from multiple sources, and who suffered from both acute and chronic sciatica: sub-
group analysis specifically targeting CS was not performed (7).  Perhaps more 
importantly, no adequately-powered direct ‘head-to-head’ study, which has 
compared PGB with any drug (including GBP), exists.  
Our study therefore represents the first prospective randomised cohort of patients 
with CS to comprehensively assess the ‘head-to-head’ efficacy of PGB and GBP, 
the associated frequency and severity of AE, and the impact of PGB-GBP 
interchange.   
5.4 Methods 
5.4.1 Trial Design and Oversight 
The study design used was a prospective, single-centre, double-blind, randomised, 
double-dummy, cross-over in patients with CS (Figure 4.1). The trial was conducted 
in accordance with the SPIRIT statement and procedures following Good Clinical 
Practice (GCP) principles (8). The trial protocol has been published previously and is 
available in open access full text (9). The trial was initiated by the investigators and 
funded by an internal hospital grant. No drug company had any involvement in drug 
supply, trial conduct or manuscript review.  
5.4.2 Eligibility and Recruitment 
Patients attending a specialist neurosurgery clinic in a large tertiary hospital, with 
unilateral CS, were considered for trial recruitment. CS was defined as pain lasting 
for at least 3 months (3) radiating into one leg only to, at, or below the knee level. 
Imaging (MRI, with or without CT) corroborating a root-level lesion concordant with 
symptoms and/or signs was determined by the trial clinician. Inclusion criteria also 
included patients being naïve to both GBP and PGB, patients 18 years of age or 
older, and patients with a sufficient understanding of English (or an available 
appropriate interpreting service) to complete the study treatments and assessments. 
Concomitant medications (including analgesics) could be continued as long as the 
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dose was stable 30 days prior to the start of the study.  No more than 2 dose 
modifications were permitted throughout the study period.    
Patients were excluded from the trial if they: were pregnant, breastfeeding or women 
planning conception during the study period; had a history or diagnostic results 
which suggested an inherited neuropathy, or neuropathy attributable to other causes 
(hypothyroidism, B12 deficiency, connective tissue disease, amyloidosis, toxic 
exposure); had a major organ system disease; had cardiovascular autonomic 
neuropathy; had baseline postural hypotension of more than 20mm Hg; had specific 
contraindications to PGB or GBP (allergy to, or significant renal impairment); had 
cancer, dementia, severe mental illness or other condition which would significantly 
reduce their ability to consent and/or fully undertake the program; were unlikely to 
comply with study procedures (e.g. those with high opiate/opioid tolerance, 
inconsistent clinic attendances etc.). Since PGB and GBP are both predominantly 
renally excreted, patients with an estimated creatinine clearance of<60 ml/minute 
were also excluded. 
5.4.3 Randomisation and Blinding 
The trial pharmacist (un-blinded/independent) generated the randomisation code 
using a computer-derived permuted block with varying block size sequence. 
Manufacturing and preparation of the medication capsules was performed by an 
external GMP accredited facility. The un-blinded pharmacist was involved in 
preparing medication kits according to the trial randomisation schedule. Treatment 
was allocated according to a 2x2 sequential design where participants received PGB 
first, then subsequently GBP (or vice versa) in a double-blinded fashion. Due to the 
variability in regular dosage frequency between the medications (PGB = twice daily, 
GBP = thrice daily) study medication packs contained 3 bottles, one for each dosage 
time (morning, lunch, and night) in order to maintain blinding. Medication packs for 
the PGB arm had a placebo incorporated as the lunch time dose such that both drug 
regimens were indistinguishable. The randomisation schedule remained concealed 
from other researchers. The randomisation process ensured concealed allocation 
and blinding of the specialist, the participant and the outcome assessor during 
recruitment, data collection and analysis. 
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5.4.4 Trial Regimen and Procedures 
All patients were fully informed of the possible types of AE associated with either 
GBP or PGB, as listed in the AMH (11), prior to participation.  Participants were 
randomised to commence treatment on either PGB or GBP. As a result of the cross-
over design, participants had the unique opportunity to experience both PGB and 
GBP in succession.  Because of the one-week washout period, carry-over effects 
(medium or long term) were considered improbable. Participants received standard 
neurosurgical care independent of, and parallel to, the trial.  
The starting dose of PGB was 150mg once daily for the first week. This was titrated 
to the participant’s optimal dose, up to a maximum of 300mg twice daily, depending 
on their progress and tolerance at each dose level. The starting dose for GBP was 
400mg once daily for the first week. Likewise, this drug was titrated to the 
participant’s optimal dose, up to a maximum of 800 mg thrice daily, depending on 
their progress and tolerance at each dose level. These doses are based on national 
recommendations from the Australian Medicines Handbook (10).  In the standard 
study dosing regimen, there was a 4-week titration period, after which the maximum 
tolerated dose for each participant was maintained for 4 weeks before the first study 
medication was ceased for washout. The washout period between treatment phases 
lasted for 1 week: this was deemed sufficient for these medications since they both 
possess a short half-life (5-7 hours). The dosage of either PGB or GBP could be 
amended at any stage in the trial based upon efficacy and/or AE by communication 
between the study specialist and the study pharmacist. The maximum treatment 
period was 8 weeks for each medication (11). 
Participants could continue concomitant medications (including analgesics) 
throughout the study period, given the stipulations stated above. Such concomitant 
medications were closely monitored and recorded as part of the case report form. 
Note that this practice is entirely consistent with NICE-UK guidelines, which state 
that, when super-adding second-line agents for analgesic control (such as GBP and 
PGB), “overlap with first-line agents is encouraged to avoid decreased pain-control”. 
To our knowledge, only one prospective cohort study has reflected this practice, with 
GBP in CS (12). However, participants did not take concomitant medications that 
were contraindicated because of a known interaction with PGB or GBP (10). No other 
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pain interventions were permitted throughout the period of study: if considered 
necessary, such patients were withdrawn from the trial. 
5.4.5 Outcomes and Data Collection 
The primary outcome was leg pain intensity using the Visual Analogue Scale (VAS). 
Participants were asked to rate their average leg pain over the last 24 hours out of 
10, with zero representing ‘no leg pain’, and 10 representing the ‘worst pain 
imaginable’ (4). A clinically important minimum difference of 1.5 points was chosen 
based on previous literature (13). 
The key secondary outcome was the Oswestry Disability Index (ODI) questionnaire 
(4), to assess disability where scores range from 0 to 100, with higher scores 
indicating greater disability.  The clinically important difference is represented by 10 
points (14).  
Details of AE were collected throughout the course of the trial and were noted as a 
description including a 0 to 10 score for both frequency and severity, whereby an 
increasing number denotes a higher frequency or severity. Outcomes were 
assessed at baseline, then at weeks 4, 8, 10, 14 and 18.  Baseline, week 8, 10 and 
18 were considered the primary time points for the primary outcome which 
represented the start and finish of each medication.  
Data collection was conducted by the study researchers from telephone, email or 
online. Week 10 data collection served as the cross-over secondary baseline for the 
purpose of analysis. Data was entered into Case Report Forms by dedicated trained 
staff. 
Adherence to study medication was documented through a self-reported daily 
medication diary, and by counting the returned medicine. 
5.4.6 Statistical Analysis 
It was estimated that a sample of 38 patients would be required to provide the trial 
with 80% power to detect a conservative minimum between-treatment difference of 
0.9 points in the pain score on the 10 point scale at week 8 and 18, and to detect a 
74 
 
clinically important between-treatment difference of 10 points on the ODI at the 
same assessment interval. These assumptions included a standard deviation (SD) 
of the difference between the two same values for the same patient of 1.2 points 
(given a cross-over study design) and a two-sided alpha level of 0.05. The estimated 
sample size would also allow for a drop-out rate of 20%. 
Because of our study representing the first ‘head-to-head’ trial between PGB and 
GBP, an interim analysis was planned at 50% sample size to assess AE and 
efficacy, and to confirm trial viability. No formal stopping rules were used due to the 
lack of previous ‘head-to-head’ data enabling the pre-setting of boundaries.  Instead, 
the investigators and independent trial monitor would make a judgment based on 
AEs and outcomes in the primary measure. Missing data was handled by a single 
imputation method whereby the last observation is carried forward and used as a 
surrogate for the missing value. This is the favoured approach for replacing missing 
data as it is conservative, yields an appropriate estimate of variation in outcome and 
is unlikely to bias towards the alternative hypothesis (15).   
Data was de-identified prior to interim statistical analysis and performed on an 
‘intention-to-treat’ basis. Unadjusted mean ± SD were calculated and presented for 
descriptive statistics of the population. Normality of data distribution was assessed, 
and the appropriate t-tests performed for between-groups differences including 
repeated measures linear models. Binary variables were tested using Chi-square 
analysis. Statistical significance was set at a two-sided P value of less than 0.05. 
The frequency and severity of AE were reported descriptively with calculated mean 
± SD based on unadjusted mean scores of patients. Data imputations were not 
required since less than 5% of the primary outcome data were missing. Analyses 
were performed using both Microsoft Excel and SPSS statistical software version 
22.  
5.5 Results 
N=20 participants underwent randomisation from March 2016 to March 2018.  This 
equated to n=40 drug and patient episodes. N=2 were excluded. N=10 were 
allocated to receive GBP followed by PGB, and n=10 PGB to receive followed by 
GBP (Figure 4.1 ). After randomisation, 2 patients were excluded from analysis.  
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Both drop-outs had been randomised to the ‘GBP-then-PGB’ sequence.  One 
patient had failed to collect study medication and was subsequently lost to follow-
up. Each participant reached maximal dosing for the medications with <10% 
requiring any dose reductions (either temporary or permanent).  
The total trial population (n=18) experienced efficacy in VAS-reduction and ODI-
reduction with the medication regimes. Two-thirds (n=12, 67%) of the population 
reported at least one AE while in the trial. Over half of the population (n=10) where 
taking concomitant paracetamol alone or in combination with codeine, while one 
third of the population were stable on a background opioid before and during the 
trial (Table 5.1). 
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Table 5.1 Patient characteristics – total population 
Description Value P – value 
(if applicable) 
Total population – n (%) 18 (100) - 
Age (years) - mean (range) 57 (22 – 80) - 
Smokers - n (%) 5 (28) - 
Alcohol intake – n (%) 12 (67) - 
Male         11(61) 0.230 
Female 7(39)  
Adverse events – n (%) 12(67) - 
Efficacy - n (%) 18(100) - 
Concomitant medications – n (%) 
NSAIDS 3 (17) - 
Paracetamol (+/- codeine) 10 (56) - 
Opioid 6 (33) - 
Antiepileptic/anticonvulsant 1 (5) - 
 
5.5.1 Efficacy 
At the end of an 8-week treatment period, a significant VAS-reduction was recorded 
for both GBP (7.54±1.39 to 5.82±1.72, P<0.0001) and PGB (7.33±1.30 to 6.38±1.88, 
P=0.002) (Table 5.2). A significant ODI-reduction was also observed at 8 weeks for 
both GBP (59.22±16.88 to 48.54±15.52, P=<0.001) and PGB (59.22±13.24 to 
50.44±16.58, P<0.001) (Table 5.2). 
When unadjusted mean differences in VAS-reduction were compared ‘head-to-
head’, GBP proved superior (GBP 1.72±1.17 versus PGB 0.94±1.09, P=0.035) 
(Table 5.2).  However, when unadjusted mean differences in ODI-reduction were 
compared ‘head-to-head’, no significant difference was found (GBP: 10.66±9.90 
versus PGB: 8.78±8.86, P=0.63) (Table 5.2). 
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Table 5.2 Efficacy for total population.   
Gabapentin 
VAS 
Start – mean ± SD 7.54 ± 1.39  <0.001 
Finish – mean ± SD 5.82 ± 1.72  
ODI 
Start – mean ± SD 59.22 ± 16.88 <0.001 
Finish – mean ± SD 48.54 ± 15.52  
Pregabalin 
VAS 
Start – mean ± SD 7.33 ± 1.30 0.002 
Finish – mean ± SD 6.38 ± 1.88  
ODI 
Start – mean ± SD 59.22 ± 13.24 <0.001 
Finish – mean ± SD 50.44 ± 16.58  
Head-to-head 
VAS 
Drug GBP – mean difference ± SD 1.72 ± 1.17 0.035 
Drug PGB – mean difference ± SD 0.94 ± 1.09  
ODI 
Drug GBP – mean difference ± SD 10.66 ± 9.90 0.631 
Drug PGB – mean difference ± SD  8.78 ± 8.86  
*efficacy defined as reduction in VAS and/or ODI from both PGB and GBP 
5.5.2 Adverse Events  
Thirty-eight AEs (21 types) were reported in 12/18 (67%) of patients at some stage 
in the study. The most common AEs overall were dizziness (5/38, 13%), drowsiness 
(5/38, 13%) and nausea (4/38, 11%). There were significantly more AEs associated 
with the PGB arm than with GBP (n=31 v n=7, P=0.002) (Table 5.3, Table 5.4, Table 
5.5).  
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Table 5.3 Adverse events experienced by population 
PREGABALIN 
Description Prevalence  
(No. of 
recordings) 
Proportion of 
population with 
AE (%) 
Nausea, Vomiting, Headache 7 39 
Bowel Disturbance 5 28 
Diplopia, Dysarthria  5 28 
Dizziness, Vertigo 4 23 
Drowsy, sedation 3 17 
Lethargy, numbness 2 11 
Dry Mouth 1 6 
Alertness 1 6 
Weight Gain 1 6 
Erectile Dysfunction 1 6 
Psychiatric Disturbance 1 6 
TOTAL 31  
 
GABAPENTIN 
Description Prevalence  
(No. of  
recordings) 
Proportion of 
population with 
AE (%) 
Drowsy, sedation 3 17 
Dizziness, Vertigo 2 11 
Nausea, Vomiting, Headache 1 6 
Alertness 1 6 
Total 7  
 
SUMMARY 
 Gabapentin Pregabalin P-value 
Count (N) 7 31 0.002 
Frequency (Mean) 4.71 5.51 0.83 
Severity (Mean) 4.57 6.03 0.71 
*frequency and severity measured on a scale of 1 to 10 with 10 being the worst possible score. 
NB: The same participant may have experienced multiple adverse events of different descriptions. 
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Table 5.4 Interchangeability of Gabapentin and Pregabalin 
Description SEQUENCE P-value 
 GBP to PGB PGB to GBP  
Patients (n) 8 10 - 
Adverse events          
Drug 1 (n) 3 21 - 
Drug 2 (n) 10 4 - 
VAS                
Drug 1 mean reduction (range) 1.35 (0.5-2.9) 1.43 (0.1-4.2) 0.62 
Drug 2 mean reduction (range) 0.33 (0.0-0.7) 2.01 (0.6-5.5) 0.01 
P-value <0.01 0.34  
ODI 
Drug 1 mean reduction (range) 11.25 (0-30) 12.4 (2-28) 0.31 
Drug 2 mean reduction (range) 4.25 (0-12) 10.2 (0-30) 0.24 
P-value 0.14 0.36  
 
Table 5.5 Relationship of efficacy with adverse events 
Description COHORT P-value 
 With AEs Without AEs  
Patients (n) 12 6 - 
VAS               
        Gabapentin mean reduction (range) 1.63 (0.5-5.5) 1.88 (1.0-2.9) 0.91 
        Pregabalin mean reduction (range) 1.09 (0.1-4.2) 1.23 (0.0-2.6) 0.81 
P-value 0.27 0.08  
ODI 
        Gabapentin mean reduction (range) 9.33 (0-30) 13.33 (0-30) 0.04 
        Pregabalin mean reduction (range) 10.66 (2-28) 5.00 (0-12) 0.18 
P-value 0.79 0.09  
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When the per-patient recorded AEs were clustered based on body system affected, 
into central nervous system (CNS), respiratory, gastrointestinal and genitourinary, 
both GBP and PGB demonstrated predominantly ‘CNS’ AE. However, PGB was 
associated with more severe central nervous system AE than GBP (P=0.01). 
5.5.3 Interchangeability 
A total of 8 patients completed the ‘GBP-then-PGB’ sequence, while 10 patients 
completed the ‘PGB-then-GBP’ sequence (Table 5.4). Table 5.4 clearly shows that 
GBP demonstrated superior efficacy in VAS-reduction irrespective of the sequence 
order.  Specifically, in the ‘GBP-then-PGB’ sequence, there was a significantly 
greater mean VAS-reduction associated with GBP than with PGB (GBP:1.35 v 
PGB:0.33, P<0.01). Likewise, in the ‘PGB-then-GBP’ sequence, there was a 
significantly greater mean VAS-reduction with GBP (PGB:0.33 vs GBP:2.01, 
P=0.01).  
However, ODI severity was not significantly reduced by cross-over (Table 5.4).  
Notably, both PGB and GBP demonstrated a clinically important mean ODI-
reduction at the start of treatment (PGB:12.4 and GBP:11.25), with only the ‘PGB-
then-GBP’ sequence continuing the trend of a mean clinical important result solely 
for GBP (PGB:4.25 and GBP:10.20).  
Table 5.5 shows that sequence order affected AE only with PGB.  Thus, while GBP-
AE occurred at similar frequency irrespective of sequence order, PGB-AE were 
significantly affected by sequence order.  Specifically, PGB-AE were doubled when 
PGB was prescribed first.  Thus, AE in the ‘PGB-then-GBP’ sequence was GBP: 
n=3 and PGB: n=21 compared to GBP: n=4 and PGB: n=10 in the ‘GBP-then-PGB’ 
sequence. 
5.5.4 Reduced Disability (ODI) Efficacy in those with Adverse Event  
Table 5.5 shows that AE specifically tended to affect ODI severity only with GBP. 
Specifically, efficacy was significantly less in those with AE (P=0.04, Table 5.5). 
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5.6 Discussion 
PAGPROS protocol required the Independent Data Monitor to review data after 50% 
of participants were recruited. The predetermined criteria for stopping the trial was 
a significant difference in recurrence rates or incidence of AE between groups. 
Simultaneously, the trial would have considered to be stopped if any superiority was 
observed between the medications.  After consultation in March 2018, the 
Independent Data Monitor made a recommendation to the investigators that 
stopping the trial early was justified.  
This pre-determined interim analysis of PAGPROS showed that, while PGB and 
GBP were both significantly efficacious in reducing pain intensity in patients with CS, 
GBP was superior when compared ‘head-to-head’. Moreover, GBP was associated 
with fewer and less severe AE irrespective of the sequence order.  However, while 
PGB and GBP were both significantly efficacious in reducing pain-associated 
disability (ODI), neither was superior when compared ‘head-to-head’. 
PAGPROS was adequately powered to detect a conservative difference between 
medications of 0.9 points out of 10 on the pain intensity score. The authors 
acknowledge the current clinically important treatment effect of 1.5 points out of 10 
for pain intensity, and 10 points out of 100 for disability severity. Our results showed 
that GBP was the only medication to show a clinically important difference in VAS-
reduction (mean: 1.72±1.17) and ODI-reduction (10.66±9.90). Compliance with the 
medication regimen was high based on patient diaries and pill containers returned 
at each visit. Our selection criteria were based on an established definition of CS 
with one specialist neurosurgeon involved in screening and recruitment for 
consistency. The dose of the medications was adjusted using an increasing titration 
schedule with AE monitoring according to National Formulary recommendations (10). 
The ‘cross-over’ methodology chosen for this trial provides many advantages and 
particularly strengthens the study findings. In clinical trials, a ‘cross-over’ design 
should be limited to a disease which is both chronic and stable, and for which 
treatments should not result in a total cure but, instead, only alleviate the condition. 
CS, and treatment with either PGB or GBP, satisfied both these criteria: particularly 
considering that PGB and GBP are currently considered equivalent. PAGPROS 
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therefore achieves a more efficient comparison of treatments than is possible with 
a parallel trial design. Any potential disadvantage relating to a ‘carryover effect’ 
between medications in sequence was obviated by having set the washout period 
to more than 6 half-lives of either PGB or GBP (effectively, 1 week).   
Notably, PAGPROS showed that PGB-AE were more frequent and severe when 
PGB was taken first prior to GBP. This suggests that GBP may in some way 
‘sensitize’ tissues such that, despite subsequent wash out, tolerance to PGB-AE 
was significantly enhanced.  If so, then putative PGB-induced ‘sensitisation’ did not 
appear to affect tissue tolerance to GBP: GBP-AE were significantly lower 
irrespective of sequence order. Given these findings, PAGPROS suggests that GBP 
should be commenced before PGB to permit optimal cross-over wherever PGB may 
ultimately be warranted.   
5.7 Conclusion 
PGB and GBP were both significantly efficacious. However, GBP showed a modest 
superiority and tolerability. Therefore, GBP should be considered before PGB to 
permit optimal cross-over. 
5.8 Limitations 
5.8.1 Low Recruitment Frequency 
Reflects the difficulty associated with recruiting patients with CS who have not 
already been prescribed either PGB or GBP by practitioners in either primary or 
tertiary care.   
5.8.2 Treatment Duration Effects  
The duration of the study for each participant is 8 weeks. In some rare cases, this 
might be considered insufficient time to test efficacy at the optimum dose (4).  
5.8.3 Treatment Dosages 
Given the restricted doses and study time available in PAGPROS, it was not 
possible to introduce either drug in ‘low and slow’ fashion. Since the latter potentially 
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off-sets the development of AE (4), PAGPROS may therefore potentially over-
estimate AE with either drug. Moreover, the maximal dose of gabapentin 
prespecified in the study design is lower than what can be prescribed, and was 
compared to the maximal dose of pregabalin. 
5.8.4 Maintenance of Background Therapies Including Prior Analgesia 
This may affect both efficacy and AE development: potentially increasing both. 
However, note that this practice is entirely consistent with NICE-UK guidelines (4, 16); 
and, indeed, standard clinical practice. 
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Chapter 6 The Relationship between Health Locus of 
Control and Anti-Neuropathic Drug Efficacy in 
Patients with Chronic Sciatica 
‘The best preparation for tomorrow is doing your best today’. 
H. Jackson Brown, Jr. 
6.1 Background 
Recent studies (4-7) have demonstrated that cognitive and psychological factors are 
significant in the development and persistence of neuropathic pain (NP) conditions. 
We explore the use of a Brazilian–Portuguese adapted Health Locus of Control 
(HLoC) survey for patients receiving medication treatment intervention for chronic 
sciatica (CS), with the hypothesis that patients with a higher external locus of control 
will have poorer medication efficacy outcomes and thus will negatively influence the 
prognosis of CS. 
Chapter 6 of this thesis, entitled “The Relationship between Health Locus of Control 
and Anti-Neuropathic Drug Efficacy in Patients with Chronic Sciatica” is based on 
the manuscript submitted to the Pain Medicine journal. The paper is inserted into 
this thesis with minor modifications. Only the formatting of section sub-headings 
and numbering of tables and figures have been modified from the original 
publication to match the thesis format. The referencing of this chapter retains the 
original journal style. 
Robertson K, Plummer D, Marshman L, (2018). The Relationship between 
Health Locus on Control and Anti-Neuropathic Drug Efficacy in Patients with 
Chronic Sciatica. Pain Medicine (submitted 12.10.2018). 
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6.2 Abstract 
Setting: Psychological and personality factors may be significant in the 
development and persistence of NP, such as CS. Specifically, patients with an 
‘external’ HLoC orientation reportedly experience poorer medication efficacy with 
NP. HLoC-scores (‘internal’/‘chance’/‘external’) measure a patient’s sense-of-
control over their own health, and their ability to influence outcomes.   
Objective: To investigate any relationship between HLoC and efficacy with PGB 
and GBP in CS. 
Subjects and Methods:  The study formed part of a recently-published novel 
prospective randomised controlled double-dummy cross-over ‘head-to-head’ trial of 
PGB and GBP in CS. An adapted HLoC questionnaire, Visual Analogue Scale (VAS) 
and Oswestry Disability Index (ODI) were administered. HLoC-scores were used to 
prospectively dichotomize: 1) patients predominantly with ‘internal’-HLoC scores 2) 
patients predominantly of ‘external’-HLoC scores. 
Results: Across n=38 drug-patient episodes, ‘external’-HLoC was correlated with 
baseline ODI.  Within each HLoC group, GBP and PGB both displayed significant 
VAS and ODI reductions at each interval.  However, when VAS and ODI were 
averaged over the entire study, ‘external’ HLoC significantly improved only ODI with 
GBP, not PGB.  Further, ‘external’-HLoC was correlated with decreased 
improvement in VAS and ODI solely with PGB, not GBP.  After cross-over, patients 
taking PGB progressed to a higher ‘external’-HLoC level.  PGB alone demonstrated 
a significant positive correlation between ‘external’-HLoC and VAS (r=0.62, 
p=<0.05). 
Conclusion: CS patients with an ‘external’-HLoC showed a higher disease 
disability. This affects anti-neuropathic drug efficacy. Specifically, CS patients with 
personality traits of an external locus nature, were less likely to benefit from 
treatment with PGB. Moreover, HLoC can shift and should not be taken as a fixed 
value.   
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6.3 Introduction 
Sciatica is a form of radicular pain characterised by buttock or hamstring discomfort 
which typically radiates to below knee level. It may also be accompanied by sensory 
loss, motor weakness and reflex diminution in the affected lower limb. Sciatica is 
caused by either compression, or irritation, of the roots or nerves which together 
form the sciatic nerve (1, 2). 
However, the term “sciatica” is used by clinicians in different ways; some refer to 
any leg pain originating from the back as sciatica; others prefer to restrict the term 
to pain originating from the lumbar nerve root. Others believe sciatica is a form of 
NP which is bundled with other NP such as chronic low back pain (CLBP) (1, 2). CS 
is persistent sciatica for more than 3 months otherwise refractory to conservative 
measures (3). 
The annual incidence of CS is estimated to be between 1.6% and 43% (2).  A large 
proportion of patients with CS suffer persistent pain for two years or longer (1), which 
contributes to absence from employment and workers compensation claims. While 
clinicians adopt guidelines to provide general recommendations for prescribing 
analgesics to treat CS, the associated cognitive and psychological factors which 
affect the outcomes of treatment are not well understood. 
Recent studies have demonstrated that cognitive and psychological factors are 
significant in the development and persistence of NP conditions (4-7). The HLoC is 
one of the most frequently investigated patient decision-making frameworks in 
neuropathic conditions (5, 6, 8, 9) and is defined as the perceived control the individual 
has over his or her own health (4, 10). 
HLoC can be classified as internal (individuals believe that they are responsible for 
their own health outcomes), external (the belief that other people are responsible for 
health outcomes) or by chance (the belief that health relies on chance) (4, 10, 11). 
Individuals with an ‘external’ locus of control reportedly allow their clinicians to take 
a more paternalistic approach, with the patient participating less in treatment 
decisions. Individuals with a higher ‘internal’ locus of control prefer to participate in 
treatment decisions, and be part of an active alliance between the clinician and the 
patient (4, 10, 11).  
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Studies of HLoC in patients with CLBP have shown that a bias towards an ‘external’-
HLoC negatively influences the prognosis of CLBP (5, 8), and has an increased 
association with depression (7). Conversely, people with CLBP who have an ‘internal’ 
HLoC show lower levels of disability after treatment when compared to individuals 
with an external HLoC (8). Although these correlations of locus of control to disease 
outcome have been studied for CLBP, these studies are both dated and not specific 
to the condition of CS. To date, there has been no study to examine the locus of 
control for CS patients and association to medications.  
The present study aimed to test these theories in a population with CS who were 
enrolled in a previously published prospective randomised controlled double-dummy 
cross-over trial of PGB and GBP use in CS (12). The HLoC scale, developed by 
Wallston et al (11), is frequently used for patients with NP (5, 8). This questionnaire has 
three subscales, which measure the internal, external and chance health locus of 
control of the participant (4, 10, 11). Recently, a Brazilian–Portuguese version of an 
adapted HLoC scale was developed and validated for use specifically in NP (13).    
We used the adapted HLoC scale for patients receiving medication for CS to test 
the hypothesis whether patients with a higher external HLoC experience a poorer 
efficacy and outcome after treatment with GBP or PGB. 
6.4 Objective 
To investigate the relationship between HLoC scores and efficacy of medication 
interventions (PGB versus GBP) as measured by changes in a Visual Analogue 
Score (VAS) and in the Oswestry Disability Index (ODI) 
6.5 Methods 
The study was performed as part of a prospective randomised controlled double-
dummy cross-over trial of PGB and GBP in CS (14). Participants were randomised in 
a double-blinded fashion to a treatment regime.  Either GBP or PGB was 
continuously taken until a planned one-week washout period, after which 
participants were crossed over to the other drug. Participants were monitored by the 
trial pharmacist to ensure compliance with the medication regime and collection of 
data.  Efficacy was assessed by recording VAS and ODI (15).  The ODI is the ‘gold 
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standard’ for measuring disability associated CLBP (15). On the ODI, 0-20 equates 
to ‘minimal disability’, 21-40 ‘moderate disability’, 41-60 ‘severe disability’, 61-80 
‘crippled’ and 81-100 ‘bed-bound’. Adverse events (AE) to either drug was also 
systematically documented.     
The adapted HLoC scale was administered to consenting participants of the clinical 
trial.  The validity of the adapted HLoC scale has been previously demonstrated (13). 
The scale is composed of 18 items divided into 3 loci-of-control subscales, which 
are ‘internal’ locus (6 items, questions 1, 6, 8, 12, 13, 17), ‘chance’ (6 items, 
questions 2, 4, 9, 11, 15, 16), and ‘external’ locus (6 items, questions 3, 5, 7, 10, 14, 
18).  Responses were recorded using a 6-point Likert-type rating scale, with a value 
of 1 indicating “strongly disagree” and a value of 6 indicating “strongly agree.” 
Summed subscale scores ranged from 6 to 36. The higher the participant scores for 
each subscale, the greater the locus of control on that dimension.  
The adapted HLoC questionnaire (appendix 1) was administered at baseline (before 
medication commencement and at weeks 8 (pre-washout), week 10 (secondary 
baseline) and week 18. The data for internal, chance and external sub scales of the 
questionnaire where collated and averaged for each participant.  
Averaged scores for each subscale in the HLoC questionnaire was used to 
prospectively dichotomize two study sub-groups: Group 1 ‘predominantly internal 
locus’, and Group 2 ‘predominantly external locus’. Between group means of 
‘Internal’/’Chance’ and ‘External’/’Chance’ were calculated and used to distribute, 
and thus eliminate the chance subscale evenly.  
The score on the VAS and ODI was collected for each participant at four-time points: 
T0, T1, T2 and T3. Time-point T0 and T1 relates to start and end of the first drug 
treatment respectively. Following a planned 1-week washout, T2 and T3 correspond 
to the start and finish of treatment with the second drug. Randomisation was used 
to determine which drug came first for each participant. The HLoC was assessed at 
these same time points in an interview format and thus permits correlation with VAS 
and ODI.  Averaged changes in VAS and ODI were calculated for each patient as a 
marker of pain and disability respectively.  A positive averaged reduction in VAS 
and/or ODI would be taken as reflecting efficacy of the respective medication.  
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Descriptive statistics include frequency distribution for categorical variables (gender 
and disability level), and mean and standard deviation for continuous variables (age, 
ODI) as seen in table 6.1. Statistical analysis of data was undertaken using SPSS 
version 22 software. Comparisons between two independent groups were 
performed with the independent samples t-test. Pearson’s correlation coefficient 
was calculated to examine the association between pain and disability with the 
HLoC variables. A P-value <0.05 was considered statistically significant.   
6.6 Results 
The parent clinical trial was ceased because the planned interim analysis 
demonstrated superiority of GBP over PGB (12). N=20 participants underwent 
randomisation.  This equated to n=40 drug and patient episodes. N=2 were 
excluded. N=10 were randomised to receive GBP followed by PGB, and n=10 to 
PGB followed by GBP. After randomisation, 2 patients were excluded from analysis.  
Both drop-outs had been randomised to the ‘GBP-then-PGB’ sequence.  Data was 
available on 18 patients for this secondary analysis as previously published (12). 
Further allocation into groups saw 10 patients analysed as belonging in the “internal 
locus” group and 8 in the “external locus” group respectively. Total population 
demographic data are shown in Table 6.1.  
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Table 6.1 Demographic characteristics of patients with chronic sciatica 
Description N % 
Total population  18  100 
Gender 
                  Male 
                  Female 
 
12 
6  
 
66 
34 
Level of ODI 
Minimal disability 
Moderate disability 
Severe disability 
Crippled 
Bed-bound 
 
Nil 
4 
5 
8 
1 
 
0 
23 
28 
44 
5 
 Mean + SD 
Age (years) 57.11 16.50 
ODI 
T0 
T1 
T2 
T3 
VAS 
T0 
T1 
T2 
T3 
 
59.22 
48.55 
59.22 
50.44 
 
7.54 
5.82 
7.32 
6.38 
 
16.89 
15.53 
13.25 
16.58 
 
1.39 
1.72 
1.30 
1.88 
6.6.1 Pain Severity 
Pain severity was significantly reduced by each drug within each group at the end 
of each treatment (P=<0.05). Furthermore, pain severity (VAS) at baseline time 
points T0 and T2 and at end-of-treatment timepoint T1 were the same in both 
‘internal HLoC’ and ‘external HLoC’ groups (P=>0.05) (Table 6.2). However, pain 
severity at end-of PGB treatment timepoint T3 was significantly different between 
‘internal HLoC’ and ‘external HLoC’ groups, with PGB having a higher VAS score 
for pain (P=<0.05). 
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6.6.2 Disability Severity 
ODI at timepoint T0 showed significant disparity, with “external”-HLoC patients 
demonstrating a higher ODI (P=<0.05) (Table 6.2). This timepoint correlates to the 
start of GBP treatment. All remaining ODI timepoints between groups were not 
significantly different. ODI severity within each group was significantly reduced by 
each drug (P=<0.05). 
Results for average medication efficacy between groups showed variabilities (Table 
6.2). There was no difference for internal locus patient’s outcome scores for either 
VAS or ODI for either medication. Conversely, a significant difference, both within 
group and between groups, was observed for external locus patients, who 
experienced a reduced outcome from PGB in both VAS and ODI (P=<0.05).  
6.6.3 Health Locus of Control Effect with Interchange 
A total of 8 patients completed the ‘GBP-then-PGB’ sequence, while 10 patients 
completed the ‘PGB-then-GBP’ sequence (table 6.4). Table 6.4 shows that a 
significant shift occurred in the ‘external’ locus subscale after treatment with PGB 
when GBP was the predecessor. No other significant different shifts were observed 
locus of control scales between the drug sequences.  
6.6.4 Health Locus of Control Correlation with Efficacy 
The relationship between subscales of HLoC with pain severity (VAS) and ODI at 
each time point for the total population is shown in table 6.3. A significant positive 
relationship was found between the external HLoC and VAS after PGB (r=0.62, 
p=<0.05).  There were no other significant correlations between the ‘internal’ and 
‘chance’ HLoC factors with either VAS or ODI. 
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Table 6.2 Results of medication efficacy according to pre-defined Health Locus of 
Control study group.   
*considered statistically significant – P=<0.05 
Description 
Group 1 
Internal Locus 
(n = 10) 
Group 2 
External Locus 
(n= 8) 
P value 
Demographics 
Age years - (Mean SD) 
Gender - (Male %, n) 
Smoker (%,n) 
Alcohol intake (%,n) 
Ethnicity (%,n) 
- Caucasian 
- Italian 
- ATSI 
 
58.3 (13.04) 
60%(6) 
30%(3) 
50%(5) 
 
80%(8) 
10%(1) 
10%(1) 
 
55.6 (20.93) 
63%(5) 
25%(2) 
88%(7) 
 
62%(5) 
25%(2) 
13%(1) 
 
0.988 
1.00 
1.00 
0.151 
 
- 
- 
- 
Pain Severity (VAS) 
T0 –baseline 
T1 – End Gabapentin 
P-Value 
T2- baseline 2 
T3 – End Pregabalin 
P-Value 
 
7.39 (1.76) 
5.59 (2.06) 
0.003 
6.86 (1.47) 
5.52 (2.04) 
0.012 
 
7.73(0.81) 
6.13 (1.27) 
<0.001 
7.91 (0.80) 
7.46 (0.91) 
0.003 
 
0.560 
0.454 
 
0.073 
0.026 
Disability Severity (ODI) 
T0 –baseline 
T1 – End Gabapentin 
P-Value 
T2- baseline 2 
T3 – End Pregabalin 
P-Value 
 
53.00 (19.62) 
48.20(17.24) 
0.006 
58.20 (15.18) 
45.80 (19.14) 
0.003 
 
67.00(8.55) 
49.00(14.26) 
0.001 
60.50 (11.25) 
56.25 (11.28) 
0.018 
 
0.028 
0.757 
 
0.596 
0.076 
Treatment Outcomes  
Average VAS reduction 
Gabapentin 
Pregabalin 
P-Value 
Average ODI reduction 
Gabapentin 
Pregabalin  
P-Value 
 
 
1.80 (1.44) 
1.34 (1.35) 
0.435 
 
4.80 (4.35) 
12.40(10.19) 
0.052 
 
 
1.61 (0.80) 
0.45 (0.30) 
0.004 
 
18.00(10.19) 
4.25 (3.91) 
0.014 
 
 
0.812 
0.042 
 
 
0.005 
0.008 
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Table 6.3 Correlation between Health Locus of Control and ODI, VAS for the total 
population 
Description 
Internal 
Pearson’s r 
Chance 
Pearson’s r 
External 
Pearson’s r 
Pain Severity (VAS) 
T0 –baseline 
T1 – End Gabapentin 
T2- baseline 2 
T3 – End Pregabalin 
 
0.06 
0.03 
-0.12 
-0.16 
 
0.10 
0.17 
0.22 
0.33 
 
0.20 
0.23 
0.36 
 0.62* 
Disability Level (ODI) 
T0 –baseline 
T1 – End Gabapentin 
T2- baseline 2 
T3 – End Pregabalin 
 
-0.29 
0.09 
0.10 
-0.15 
 
0.28 
0.26 
0.43 
0.34 
 
0.38 
0.19 
0.19 
0.33 
*considered statistically significant – P=<0.05 
 
Table 6.4 Interchangeability and effect on Health Locus of Control 
GBP to PGB (n=8) HLoC Subscale 
 Internal Chance External 
T0 (avg) 21.2 16.6 21.4 
T1 (avg) 21.0 16.1 21.2 
WASHOUT 
T2 (avg) 21.6 15.3 22.7 
T3 (avg) 21.3 16.7 22.7 
P-value (drug 1 vs drug 2) 0.41 0.63 0.01 
PGB to GBP (n=10) HLoC Subscale 
 Internal Chance External 
T0 (avg) 21.5 17.8 20.4 
T1 (avg) 22.4 17.4 20.5 
WASHOUT 
T2 (avg) 22.4 16.7 21.6 
T3 (avg) 21.9 17.8 21.2 
P-value (drug 1 vs drug 2) 0.79 0.54 0.38 
*considered statistically significant – P=<0.05 
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6.7 Discussion 
This present study supplements a recently published clinical trial which compared 
GBP and PGB efficacy and adverse events (AE) in CS (12). The PAGPROS trial 
results revealed that GBP was more effective than PGB for treating CS, and that 
GBP was associated with fewer and less severe AE. In accordance with another 
prior study (3), AE were significantly associated with decreased ODI efficacy; 
specifically, with GBP (3, 12).  Importantly, AE with PGB were both more frequent and 
severe when PGB was trialled first (12).  This potentially suggested that GBP may 
‘prime’ tissues against PGB-related AE.  The overall study conclusion was therefore 
that GBP should be considered before using PGB in CS (12).  Notably, this conclusion 
is contrary to current NICE UK guidelines regarding PGB and GBP (16).    
However, in addition to assessing such core outcomes, in the current study we also 
examined whether certain personality characteristics could, in turn, influence 
treatment outcomes. The HLoC score was used as a surrogate marker for 
‘personality’: notably, for whether the patient was more oriented towards ‘self-
control’ (‘internal’ HLoC) or whether, instead, they were more susceptible to allowing 
others to take control of their health (‘external’ HLoC).  To our knowledge, this is one 
of the first studies to explore such an association between HLoC and medication 
efficacy, AE or tolerance in patients with CS.  
Analysis showed that patients with higher baseline ‘external’ HLoC score also had 
a higher baseline ODI.  Because the ODI is self-rated, one possible interpretation is 
that those with an ‘external’ HLoC potentially over-estimated their degree of CS-
related disability.  However, another possibility is that CS of a severity which causes 
greater disability, over time, potentially encourages or predisposes patients to move 
more towards an ‘external’ HLoC score.  That is, over time, persistent pain and 
disability may lead to an attrition of ‘self-control’.  On this scheme, therefore, HLoC 
may be more ‘dynamic’ than is often assumed.    
As with the PAGPROS Trial results (12), within each HLoC group, GBP and PGB 
both displayed significant VAS and ODI reductions at each pre-determined time 
interval.  However, those with a higher ‘external’ HLoC experienced less 
improvement in either VAS or ODI while taking PGB. This suggests that treatment 
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outcomes with PGB may, to some degree, be influenced by personality or 
psychological factors.  Furthermore, following cross-over, patients taking PGB also 
appeared to progress from a lower to a higher ‘external’ HLoC category. 
Interestingly, while CS may affect HLoC change over time, the latter result suggests 
that drugs such as PGB may be associated with more rapid HLoC change. This 
further supports the possibility that HLoC status may be more ‘dynamic’ than is often 
assumed.   
Despite the fact that GBP and PGB both displayed significant VAS and ODI 
reductions at each pre-determined time interval, when VAS and ODI were averaged 
over the entire study period, only the ‘external’ HLoC group demonstrated 
significantly improved ODI and only with GBP.  No ODI improvement was 
demonstrated with PGB. Further, VAS was significantly correlated with ‘external’ 
HLoC solely with PGB.  Thus, VAS increased with the degree of ‘external’-HLoC 
solely with PGB. Given the progression from a lower to a higher ‘external’ HLoC 
category in those taking PGB, such results not only support the PAGPROS data (i.e. 
that GBP is superior to PGB in CS) (12), they also raise the possibility that at least 
some of this superiority may relate to personality factors, such as those manifest in 
a dynamic HLoC.    
Ultimately our results show that drug efficacy influences HLoC, and that HLoC can 
shift. Therefore, HLoC should not always be considered to be static. The reasons 
for shifting HLoC scores in individual participants over time are not clear however 
three possibilities include: First, participants with higher external HLoC scores at 
baseline were more likely to demonstrate more severe disability; that is, the greater 
the disability, the more likely they were to look to external factors, such as clinicians, 
to exercise control over their health. Perhaps, this finding is not so surprising as 
people with more severe disease may well have reached a stage where they are 
increasingly looking to others for answers. The second possibility relates to the 
impact of adverse events from the drugs, in that, treatment outcomes (esp. with 
PGB) are at least partly influenced by personality/psychological factors, perhaps 
mediated by experiencing adverse events. Finally, there seems to be a paradoxical 
effect with GBP where those with greater internal HLoC scores showed less 
improvement in disability scores than those with external HLoC, perhaps because 
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they tended to be less disabled in the first place. Despite each of these findings 
reaching statistical significance, it is possible that they are no more than statistical 
artefacts. On the other hand, for a carefully designed clinical trial, our findings do 
raise the possibility that clinical trials (and treatments) can be influenced by 
personality factors, even when the trials are double-blinded and procedures robust.  
Our study emphasizes the importance of patient’s perceptions regarding anti-
neuropathic drug regimens for CS.  It especially suggests that ‘patient profiling’, 
particularly regarding HLoC (17, 18), should be integral to shared decision making; at 
least regarding anti-neuropathic drug regimens for CS.  With recent literature 
generally emphasizing the importance of patient involvement in the decision-making 
progress (5, 8), such a view makes sense.  
6.8 Conclusion 
CS patients with an ‘external’-HLoC showed a higher disease disability. This affects 
anti-neuropathic drug efficacy. Specifically, CS patients with personality traits of an 
external locus nature, were less likely to benefit from treatment with PGB. Moreover, 
HLoC can shift and should not be taken as a fixed value.   
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Appendix 1 – Adapted Health Locus of Control Survey 
Instructions 
Each item below is a belief statement about your medical condition with which 
you may agree or disagree. Beside each statement is a scale which ranges 
from strongly disagree (1) to strongly agree (6). For each item we would like 
you to circle the number that represents the extent to which you agree or 
disagree with that statement. The more you agree with a statement, the higher 
will be the number you circle. The more you disagree with a statement, the 
lower will be the number you circle. Please make sure that you answer EVERY 
ITEM and that you circle ONLY ONE number per item. This is a measure of 
your personal beliefs; obviously, there are no right or wrong answers. 
Scoring range  
Subscale Possible Range Items 
Internal 6-36 1,6,8,12,13,17 
Chance 6-36 2,4,9,11,15,16 
External 6-36 3,5,7,10,14,18 
 
  
1. Strongly Disagree (SD) 
2. Moderately Disagree (MD) 
3. Slightly Disagree (D) 
4. Slightly Agree (A) 
5. Moderately Agree (MA) 
6. Strongly Agree (SA) 
101 
 
Questionnaire 
Question SD MD D A MA SA 
If my sciatica pain worsens, it is my own 
behaviour, which determines how soon I will 
feel better again 
      
As to my sciatica pain, what will be will be       
If I see my doctor regularly, I am less likely to 
have problems with my sciatica pain 
      
Most things that affect my sciatica pain happen 
to me by chance 
      
Whenever my sciatica pain worsens, I should 
consult a medically trained professional 
      
I am directly responsible for my sciatica pain 
getting better or worse 
      
Other people play a big role in whether my 
sciatica pain improves, stays the same, or gets 
worse 
      
Whatever goes wrong with my sciatica pain is 
my own fault 
      
Luck plays a big part in determining how my 
sciatica pain improves 
      
In order for my sciatica pain to improve, it is up 
to other people to see that the right things 
happen 
      
Whatever improvement occurs with my sciatica 
pain is largely a matter of good fortune 
      
The main thing, which affects my sciatica pain 
is what I myself do 
      
I deserve the credit when my sciatica pain 
improves and the blame when it gets worse 
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Following a doctor’s orders to the letter is the 
best way to keep my sciatica pain from getting 
any worse 
      
If my sciatica pain worsens, it is a matter of 
fate 
      
If I am lucky, my sciatica pain will get better       
If my sciatica pain takes a turn for the worse, it 
is because I have not been taking proper care 
of myself 
      
The type of help I receive from other people 
determines how soon my condition improves 
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Chapter 7 Overall Discussion and Conclusions 
‘The great art of life is sensation, to feel that we exist, even in pain.’ 
Lord Byron 
7.1 Introduction 
This thesis reviewed the literature on Pregabalin (PGB) and Gabapentin (GBP) for 
managing chronic sciatica (CS). In addition, a series of studies were undertaken to 
provide evidence of differences in treatment outcomes between these two 
medications. This concluding chapter will summarise the findings and offer clinical 
recommendations and possible future directions for the utilisation of PGB and GBP 
in the treatment of CS. 
7.2 Summary  
The overall aim of this research was to investigate the pharmacological 
management of CS, including utilisation, AEs and efficacy of two key pain 
medications, PGB and GBP. Our expectation was that both drugs would have 
positive treatment outcomes, but that there may be a difference between the two in 
terms of pain severity, disability severity and/or adverse events. To test these 
possibilities, this work was operationalised into three main parts the main findings 
of which are as follows: 
Part One: A review of the literature regarding current evidence on the use of 
PGB and GBP in CS. 
This thesis comprehensively reviewed the available literature on the use of PGB and 
GBP in CS and other neuropathic pain (NP) states. It was found that no direct head-
to-head evidence was available, and equally that there was no recent high-quality 
research to guide clinical practice. We already knew of only 2 limited specific reviews 
which accounted for the role of PGB and GBP in CS. The first emanates from NICE-
UK guidelines which in turn recommends a variety of modalities for treating 
neuropathic conditions 9. Interestingly, NICE-UK state specifically for CS “adverse 
events should be discussed with each patient, and weighed against potential 
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benefit”. While both drugs are considered efficacious, NICE-UK favours PGB based 
on weak indirect comparisons of previous research. The second and most recent 
review only included one study for each GBP and PGB 11. The authors of this work 
concluded that the best management for CS remained unclear.  
Our review by contrast included eleven studies specific for PGB and GBP in CS and 
NP conditions. Our main conclusion was that there is a global lack of consistency 
among individual formulary regulators regarding treatment preference. Our review 
confirmed the absence of any adequately powered direct head-to-head trials 
comparing PGB to GBP for the treatment of CS. 
Part Two: Compile evidence based on retrospective data on the efficacy and 
AE profiles of PGB and GBP when used to treat CS. 
The second part of this thesis compiled evidence and clinical experience with these 
drugs by employing retrospective data collection. Given the methodological 
problems encountered in previous studies (identified in part one), we set out to 
maintain representativeness in line with gold standard guidelines (NICE-UK) by 
analysing the effects of the super-addition of GBP with background therapies in CS. 
In addition, we set out to systematically record the frequency and type of AEs to 
validate and quantify anecdotal evidence of AEs emanating from routine use of GBP 
in the first instance. 
This research found compatible results with previous studies where GBP was 
efficacious in pain and disability reduction. Interestingly, our work specifically 
highlighted the effect AEs had on treatment outcomes. In fact, one-third of our cohort 
aborted the medication during the first week. Probably the most noteworthy aspect 
of this work, was the occurrence of AEs and association with decreased GBP 
efficacy. It was not immediately clear from this study as to why AEs were associated 
with decreased efficacy. Adverse psychological factors accompanying an AE could 
conceivably impact negatively on pain perception. However, this study could not 
provide any definite mechanism for the result observed and thus prospective 
randomized clinical trials are necessary.  
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Part Three: Determine the efficacy of PGB and GBP when used to treat CS. 
Sub analysis to examine HLoC in patients being treated with PBG and GBP 
for CS. 
The final part of this thesis was to assess head to head PGB and GBP when used 
to treat CS. We hypothesised that both medications have positive outcomes based 
on the previous work in parts one and two of this thesis. Nevertheless, we 
anticipated a clinical difference might exist in specific criteria such as pain and 
disability severity along with frequency and severity of AEs. As part of the trial, we 
also took the opportunity to examine whether certain personality characteristics 
influenced treatment outcomes. To our knowledge, this work represents the first 
prospective head to head clinical trial to comprehensively assess the two drugs, as 
well as examine the impact of interchange, and to explore the association between 
medication efficacy and personality traits in clinical trials. 
Notably, the clinical trial showed a difference between the drugs at the pre-planned 
interim analysis stage. GBP was superior to PGB when compared head-to-head for 
pain reduction (VAS), and was associated with fewer and less severe AEs. The 
superiority was consistent for GBP irrespective of drug sequence. Interestingly, 
there was no difference observed when compared head-to-head for reducing 
disability (ODI). Conspicuously, the research showed that PGB AEs were greater in 
frequency and severity when it was the drug taken first in the sequence prior to GBP.  
This result raises the possibility that GBP may sensitize tissues such that, despite a 
theoretically adequate wash-out, susceptibility to PGB AEs was increased. 
However, the same results were not observed when PGB was taken first. Given 
these findings, it might be prudent to commence with GBP before using PGB to 
permit optimal cross-over wherever PGB be ultimately be warranted.  
Our research additionally examined the relationship between personality traits and 
treatment outcomes. We highlight a significant difference in treatment outcome with 
an external HLoC personality score. These patients tended to have better results 
with GBP than PGB, and a subsequent positive correlation and reduced pain 
reduction with PGB. Furthermore, a patient presenting with this self-control subtype 
was more likely to have a higher disease severity.  Our work has unearthed the 
dynamic nature of HLoC and we recognise that the HLoC may well be more labile 
106 
 
than is often assumed and should not be considered a fixed value.  Furthermore, 
our results show while it is widely accepted that personality can affect treatment 
outcomes, we uncovered evidence that personality traits might also play a role in 
clinical trial outcomes. This is particularly relevant for conditions that may take a 
heavy psychological toll (such as severe pain states) and in trials with small sample 
sizes despite otherwise ‘textbook-style’ randomisation. 
7.3 Conclusions and Clinical Recommendations 
The following conclusions have been drawn and recommendations made:  
1. Until now, no direct high-quality research existed to guide treatment choice 
between PGB and GBP for CS. Further studies building on the work in this 
thesis are needed to consolidate and provide a consistent message to 
prescribers and formulary regulators. 
2. GBP and PGB were both efficacious at reducing pain and disability for CS. 
At an individual level, both drugs were significantly efficacious at reducing 
VAS and ODI scores. No literature exists on their relative efficacy by other 
scales of measurement (i.e. not VAS or ODI). In this situation, caution should 
be given to the choice of drug and we would recommend the approach taken 
by the NICE-UK guidelines “adverse events should be discussed with each 
patient, and weighed against potential benefit”.  
3. There is a difference in treatment outcomes between GBP and PGB when 
prescribed for CS. On average, GBP is superior in reducing pain severity and 
has less frequent and severe AEs. Moreover, GBP has favourable 
interchange results with no loss of efficacy and consistently lower AEs when 
compared to PGB.  This result is the cornerstone of our research. In the 
absence of any other contraindication, we recommend GBP prescription 
before trying PGB. 
4. Patients with an external self-control personality type are likely to present with 
an initial higher disability severity. Additionally, patients with an external self-
control personality type more likely to benefit from GBP rather than PGB. This 
result further adds to the evidence of a difference in response observed 
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between the two drugs. We recommend initiating treatment with GBP as this 
drug was advantageous in both personality types. 
7.4 Strengths and Limitations of this Thesis 
Each study within this thesis has included a discussion of the methodological 
strengths and limitations of the research conducted. The following paragraphs 
describe more broadly the strengths and limitations of the thesis. 
The first strength of this thesis is the use of a consistent and robust definition of CS. 
Having the research conducted within a single-centre under the guidance of a 
singular specialist provided a coherent link between the individual studies that have 
made up this thesis by publication. The use of a single specialist lens unifies the 
studies in this thesis. This approach is also principally useful as CS is commonly 
conflated with other forms of chronic low back pain and may not be well managed 
pharmacologically. This is particularly important with a current under-representation 
of CS studies worldwide 6.  
The other strength of the work in this thesis is that the studies included are supported 
by robust methodology for interventional research and contain carefully constructed 
objectives. In addition, our review adopted an all-comers approach and can be 
stated to be most comprehensive in terms of methodology, allowing for the inclusion 
of experimental, non-experimental, and varying quality studies to broadly 
understand the phenomenon explored. In our review, unlike systematic reviews, 
clinical experience of the researcher was used to test the validity of the studies and 
determine their usefulness in practice. Each study that has been published in this 
thesis has also undergone the rigorous peer review process. Careful supervisory 
oversight was also provided by experienced researchers and clinicians. 
There are a number of limitations associated with this thesis. The first is that the 
research was conducted with patients located at one regional Australian hospital, 
and as such the results may not be as generalisable to other jurisdictions with 
different regulators and methods of health provision, or with a different cultural or 
socioeconomic composition. The articles extracted for the review were managed 
using 2 reviewers and pre-defined criteria. However, the ability to replicate the same 
extraction are limited by the constantly evolving content available online. Limitations 
108 
 
also exist due to the cross-sectional design of our retrospective research in chapter 
3, where trends over time in pain severity and disability function were unable to be 
determined. Selection bias is also a possible limitation in this study due to the cross-
sectional nature of design.  Another limitation of this thesis includes the nature of 
the survey and questionnaire tools used in the clinical trial. The HLoC questionnaire 
is a self-reported tool which reflects the patients perceived locus of control at 
particular points in time, rather than their measured locus of control.  
7.5 Directions for Future Research 
This work was exploratory in nature and, although these initial results are promising, 
further research is needed to corroborate these findings and translate them into real-
world practice. Firstly, similar works to our clinical trial with a much larger sample 
size are needed to test our results. The design of future research can play an 
important role in improving the quality, and address the deficit in evidence in this 
area. Methodological quality of future studies needs careful attention. This includes 
data reporting, follow-up periods and the examination of the length of time patients 
have lived with sciatica, motivation and additional cognitive behaviour assessments. 
Secondly, in Australia, the recent addition of PGB to the PBS for NP (2013) has 
created a conflict in that some long-standing users of GBP, whose pain was 
previously well controlled on GBP, were subsequently forced to either incur greater 
costs, or to switch to PGB (with, potentially less efficacy). The Australian 
Pharmaceutical Benefits Advisory Committee rejected applications to subsidise 
GBP for the treatment of NP on the grounds of lack of evidence in the proposed 
population (i.e. clinical trial data did not reflect the population covered by the 
proposed PBS restriction) and uncertain cost-effectiveness in this patient group.  
The SPORT study16 showed that many patients with sciatica will spontaneously 
improve in the medium term with non-operative management: every attempt should 
be made to avoid a potentially unnecessary surgical procedures.  Given that some 
patients may benefit from either PGB or GBP (but not both), free interchange 
between PGB and GBP should be facilitated and not obstructed (as it is in many 
countries).   
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Last, our results confirm the serious impact that CS has and how advanced disease 
responds poorly to oral pharmaceutical intervention. Perhaps the focus should shift 
more to acute sciatica and early intervention and investigating a potentially effective 
treatment at this early stage of disease. Simultaneously, exploration of alternative 
classes of drugs or combinations of therapies should be considered due to the high 
cost of PGB and GBP. A study published in the Journal of Pain 6 showed a clinically 
important difference with the combination Buprenorphine plus PGB with no 
increased risk of serious adverse events. However, the authors do conclude that 
combining medicines may give greater pain relief compared to single-ingredient 
medicines, but the lack of studies and overall low quality of evidence limit any formal 
recommendation 6.  
7.6 Summation 
The burden of CS is considerable and optimally effective pharmacological 
intervention is paramount. However, the choice between PGB or GBP was unclear 
due to a state of equipoise in our knowledge. In this context, this research has 
achieved four important outcomes; (i) made a significant original contribution to the 
body of knowledge about optimal treatment of CS using PGB and GBP, (ii) 
documented the difference between PGB and GBP when used to treat CS, (iii) 
explored the association of cognition and personality on treatment outcomes, and 
(iv) provided evidence based recommendations that can be translated into clinical 
practice. 
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